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STRUCTURE BASED PREDICTION OF DRUG-PROTEIN INTERACTIONS 
AT ALLOSTERIC SITES: TOWARDS DIRECT INHIBITION OF THE RAS 
ONCOGENE 
Harrison Joseph Hocker, B.S. 
Supervisory Professor: Alemayehu A. Gorfe, Ph.D. 
Abstract 
Ras is a monomeric G-protein that mediates multiple signaling pathways. When bound 
to GTP, Ras binds to and activates effectors and when bound to GDP it does not. 
Somatic mutations occur in ~15% of all human cancers and cause Ras to be 
predominantly bound to GTP. Recently, several studies revealed that Ras exists in an 
ensemble of at least two states when bound to GTP. In the state 1 conformation, Ras is 
unable to properly bind effectors but holds potential for binding ligands. Conversely, at 
allosteric sites, state 2 conformations readily bind effectors but not ligands. 
 
To incorporate the flexibility of proteins into structure based drug discovery, we 
developed a protocol called LIgand Binding Specificity Analysis (LIBSA). LIBSA uses 
ligands to probe the surface of a target protein and identifies low-affinity ligands that 
bind consistently to allosteric sites. This allows for a small library of compounds to 
search for allosteric binding sites on fully flexible targets. Moreover, without the 
requirement of defining a binding site on the target, multiple pockets can be screened 
simultaneously. Using LIBSA and an ensemble of conformations, two pockets near the 
 
viii 
switch regions of Ras, switch 1 (p1) and the core β-sheet/switch 2 (p2), were found to 
bind ligands with both a high affinity and a high preference. This suggested that 
simulations coupled with docking experiments could reveal novel binding sites.  
 
As a test of this probabilistic model of binding, we investigated if the anti-cancer 
activity of Andrographolide (AGP), a medicinal extract from the plant Andrographis 
paniculata, and three derivatives (SRJ09, SRJ10 & SRJ23) was due to a direct 
interaction with Ras. Ensemble docking revealed that the SRJ compounds best-targeted 
p1 or p2. Further examination of the docked complexes using MD revealed that binding 
was stable only at p1 and not at p2. Comparison of the MD optimized complex to 
previously determined crystal structures suggested that SRJ23 could inhibit nucleotide 
exchange on Ras. Experimental validation of this hypothesis revealed that treatment of 
cells with AGP and the derivatives acutely inhibited nucleotide loading of wild type 
Ras. Amazingly, prolonged but not acute treatment of transformed cells with SRJ23 and 
SRJ09 reduced the GTP loading of K-RasG12V thus elucidating a requirement for 
exchange factors for maintenance of oncogenic Ras signaling.  
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1 
1 Introduction 
1.1 Ras & Cancer 
The Ras gene was first isolated in 1964 from rats that were known to develop sarcomas 
(Fink and Rauscher 1964, Harvey 1964) and is one of the most prolific oncogenes ever 
discovered. Ras functions as a signaling node and is regulated by the binding of guanine 
nucleotides. Classically, Ras exists in one of two states: on (GTP bound) and off (GDP 
bound). In the on state, Ras is able to efficiently bind to its downstream effectors 
(Figure 1.1) whereas in the off state it is unable to bind effectors. The GDP to GTP 
conversion is enhanced by guanine nucleotide exchange factors (GEFs) and GTP 
hydrolysis is catalyzed by GTPase activating proteins (GAPs) (McCormick and 
Wittinghofer 1996, Scheffzek 1997). Somatic mutations at positions 12, 13 and 61 lead 
to an inability of GAP proteins to accelerate GTP hydrolysis, and therefore increase the 
amount of active Ras.  
 
Figure 1.1 Structure of the Ras catalytic domain with the effector binding loops labeled 
as switch 1 and 2.  
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Humans express three isoforms of Ras: H-, N-, and K-Ras. They share more than 95% 
sequence homology in the first 167 amino acids, which defines the catalytic domain. 
The C-terminal hypervariable region (amino acids 168 to 189) serves as the membrane 
anchor, and undergoes up to 3 separate lipid modifications. All of the Ras isoforms are 
farnesylated at a cysteine residue in the C-terminal CAAX box in the ER (Hancock, 
Magee et al. 1989). Subsequently, the AAX motif is removed by Rce1 and the C-
terminal end of the protein is then carboxymethylated by Icmt (Dai, Choy et al. 1998, 
Schmidt, Tam et al. 1998). From the ER the K-Ras isoform is then trafficked directly to 
the plasma membrane by an unknown mechanism, as it only requires a single farnesyl 
modification (Hancock, Paterson et al. 1990).  The H- and N-Ras isoforms require two 
and one palmitoyl modifications respectively, and are then trafficked to the plasma 
membrane (Roy, Plowman et al. 2005). 
 
Due to the effects of the different lipid modifications, the isoforms segregate to different 
lipid environments on the plasma membrane.  Ras proteins must form clusters before 
they can activate effectors (Prior, Harding et al. 2001, Plowman, Muncke et al. 2005), 
and the presence of cholesterol controls the ability of some Ras isoforms to aggregate 
on the plasma membrane.  Both GTP and GDP bound K-Ras form cholesterol 
independent clusters (Niv, Gutman et al. 2002).  Whereas H-RasGDP and N-RasGTP form 
cholesterol dependent clusters, and H-RasGTP and N-RasGDP form cholesterol 
independent clusters.   
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Ras primarily activates two key pathways that are involved in cancer transformation: 
the mitogen activated protein kinase (MAPK) pathway and the phosphatidylinositol 3-
kinase (PI3K) pathway (Figure 1.2).  N- and K-Ras preferentially activate the MAPK 
cascade, and H-Ras preferentially activates the PI3K/Akt pathway.  
 
Figure 1.2 Ras activation of the MAPK and PI3K/Akt pathways via stimulation of a 
growth factor and activation of pathways that contribute to cancer development. 
 
Ras activation is classically driven by growth factors, which bind to receptor tyrosinse 
kinase (RTK) monomers and causes them to dimerize (Tidyman and Rauen 2009) and 
recruit GEFs, such as son-of-sevenless (SOS) (Boriack-Sjodin, Margarit et al. 1998).  
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Most relevant for cancer development, K-RasGTP drives activation of the Raf/Mek/Erk 
cascade (Bos 1989, Yan, Roy et al. 1998). Erk acts on several different targets which 
include ternary complex factors (TCFs) such as Elk-1, SAP-1, and Net (Treisman 
1994).  These TCFs induce the transcription of immediate early genes such as c-Jun, c-
Fos, and c-Myc, which function as cyclin D promoters (Chen 2003).  The increased 
concentration of cyclin D activates cyclin dependent kinase 2 (CDK2) and controls the 
G1 to S phase cell cycle restriction point.  Abnormal cell cycle progression from G1 to 
S phase has been shown to be associated with increased DNA damage and the 
development of cancer (Massagué 2004).   
 
H-Ras causes only a small portion of human cancers and it preferentially activates 
phosphatidylinositol 3-kinase (PI3K) and stabilizes its association on the plasma 
membrane (Hu, Klippel et al. 1995).  PI3K phosphorylates PIP2 to PIP3, which then 
recruits Akt/PKB (Niedergang and Chavrier 2004, Engelman 2009).  Activation of the 
PI3K/Akt pathway leads to inhibition of apoptosis, increased cellular growth, and 
proliferation by acting on the mammalian target of rapamycin (mTOR), glycogen 
synthase kinase 3 β (GSK3-β), MDM2, FOXO, and nuclear factor-κβ (Franke, Hornik 
et al. 2003, Altomare, Wang et al. 2004).  
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1.2 Overview of the Ras Structure  
The Ras catalytic domain contains a Rossmann fold (Liu, Sun et al. 1997) with 6 β-
sheets, 5 α-helices, 10 loops and 166 amino acids (Raimondi, Portella et al. 2011). The 
N-terminal, lobe 1 (first 86 amino acids) contains a large portion of the nucleotide-
binding pocket. The C-terminal lobe 2 (last 80 amino acids) interacts with the plasma 
membrane and is closest to the lipid modified HVR (Figure 1.3).  
 
Figure 1.3 β-strand 1 resides at the N-terminal part of Ras and α-helix 5 lies closest to 
the C-terminal HVR. The separation of lobes 1 and 2 occurs between β-strand 4 and α-
helix 3. (A) The lobe 1 region of Ras is colored in orange and (B) the lobe 2 region is 
colored in purple. 
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The catalytic domain of Ras transitions between two GTP-bound conformational states 
denoted as state 1 and 2 (Iuga, Spoerner et al. 2004, Spoerner, Wittinghofer et al. 2004). 
The state-2 conformation binds effectors like Raf kinase, whereas the state-1 
conformation binds with a decreased affinity (Figure 1.4). In the state-2 conformation, 
residues D33 and D38 readily form hydrogen bonds with T68, K84 and R89 on 
RafRBD. Conversely, when a state-1 conformation of Ras is placed in the presence of 
RafRBD these interactions are not formed and Y40 Ras can occupy the same space as 
R89 of RafRBD.  
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Figure 1.4 Comparison of a state-1 and a state-2 conformation of Ras positioned against 
the Ras binding domain of Raf kinase. The state-1 conformation of Ras is colored in 
orange and the state-2 conformation is colored in cyan. Both Ras-RafRBD complexes 
were sampled from MD simulations. Key residues from Raf kinase are shown in purple 
and hydrogen bonds between Ras and Raf are shown as red lines. GTP is shown in tan 
as found in the state-2 conformation.  
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Recently, the crystal structures of wild type and oncogenic H-Ras in a state-1 
conformation were solved using X-ray crystallography (Muraoka, Shima et al. 2012) by 
growing wild type or oncogenic H-Ras crystals on H-RasT35S crystals, which is known 
to exist predominantly in state-1 (Shima, Ijiri et al. 2010). Importantly, this study 
suggested that the Ras catalytic domain contains sites that are suitable for ligand 
binding.  
 
1.3 Inhibition of the MAPK Pathway: An Overview 
The mitogen activated protein (MAP) kinase pathway is named for the series of protein 
kinases that control cell proliferation, survival and growth (Seger and Krebs 1995). The 
MAPK pathway is divided into 3 separate modules: MAP kinase (MAPK), MAP kinase 
kinase (MAP2K), and MAP kinase kinase kinase (MAP3K). The members of the 
MAPK module include Erk, Jnk and p38 and are activated by the MAP2K module, 
which includes kinases such as Mek. The MAP3K module activates the MAP2K 
module and includes proteins such as Raf and PAK. The MAP3K module is the most 
structurally diverse and is activated by external signals that include stress, growth 
factors, and differentiation factors (Garrington and Johnson 1999).  
 
Multiple compounds have been developed to inhibit the MAPK cascade (Sebolt-
Leopold and Herrera 2004, Rockey and Elcock 2005). Even though there are multiple 
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components to the MAPK cascade, activation of the Raf/Mek/Erk pathway through K-
Ras has been most closely linked to the development of cancer (Roberts and Der 2007) 
(Figure 1.5).  
 
Figure 1.5 Pharmacological inhibition of the Raf/Mek/Erk pathway as well as the 
upstream RTK.   
 
Currently there are several compounds that inhibit the kinases upstream and 
downstream of Ras. The drug Erlotibnib (developed by Genentech and marketed as 
Tarceva) is used to treat lung and pancreatic cancers (Figure 1.5) by targeting the 
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EGFR. Oncogenic Raf is expressed in endogenous cancer cell lines and is responsible 
for multiple types of cancers including melanomas (Old, Shabb et al. 2009, Margolin, 
Moon et al. 2012). The drug Sorafenib (marketed as Nexavar and developed by Onyx 
and Bayer pharmaceuticals) inhibits oncogenic Raf and is currently in clinical use to 
treat thyroid, renal and liver cancer. The pharmaceutical industry has also developed 
drugs against MEK. While MEK does not have any oncogenic mutations that can cause 
transformation endogenously, constitutively active MEK does transform cells (Cowley, 
Paterson et al. 1994, Mansour, Matten et al. 1994). Therefore compounds such as 
AZD6244 (trade name Selumetinib developed by AstraZeneca) could be used to treat 
certain types of cancers. Additionally, the compound CAY10561 is an ERK specific 
inhibitor; however, it is not in clinical use.  
 
1.4 Ras Drug Development: A Historical View 
Nearly 30 years after the identification of Ras as an oncogene, there are still no 
compounds that have been brought into the clinic that effectively treat Ras mediated 
tumors. Some of the first efforts towards Ras inhibition were directed at preventing Ras 
trafficking to the plasma membrane, as it needs to be properly localized to participate in 
the MAPK pathway. It was thought that without the ability to attach a farnesyl group to 
the CAAX box, Ras transformed cells would be unable to survive. Accordingly, the 
compounds, Tipifarnib (Van Cutsem, van de Velde et al. 2004, Hong, Cabanillas et al. 
2011, Margolin, Moon et al. 2012) and Lonafarnib (Niessner, Beck et al. 2010) were 
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developed to inhibit farnesyl transferase. However, inhibition of farnesyl trasferase did 
not prevent the activity of Ras mediated cancers (Hidalgo 2010) during phase 2 and 3 
clinical trials. Even concurrent treatment of patients with Tipifarnib and other 
chemotherapies such as Gemcitabine gave no increase in clinical efficacy (Van Cutsem, 
van de Velde et al. 2004). It was later determined that there is a compensatory 
prenylation mechanism being carried out by geranylgeranyl trasferase 1. Unfortunately, 
simultaneous treatment with both a farnesyl transferase inhibitor and a geranylgeranyl 
transferase inhibitor is toxic (Lobell, Omer et al. 2001).   
 
Additional work was directed towards inhibition of the steps mediating trafficking to 
the plasma membrane by inhibiting Rce1 and Icmt (Winter-Vann, Baron et al. 2005). 
Additionally, farnesylcysteine mimetics were developed to disrupt Ras interactions with 
galectin. One such compound called Salirasib went into phase 1 and 2 clinical trails but 
operated by multiple mechanisms and it is uncertain if its effectiveness was due to Ras 
inhibition or not (Rotblat, Ehrlich et al. 2008). Recently, it has been shown that known 
pharmaceutical agents, namely Staurosporines and Fendiline, inhibit Ras function by 
redistributing it away from the plasma membrane (Cho, Park et al. 2012, van der 
Hoeven, Cho et al. 2012).  
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In the pursuit of molecules that directly bind Ras, several compounds have been 
identified that bind the Ras catalytic domain. Early work showed that zinc cyclen binds 
to a pocket formed by parts of α-helix 5, β5, β6, and the loops 7 and 9 (Spoerner, Graf 
et al. 2005, Rosnizeck, Graf et al. 2010). This compound stabilizes an inactive 
conformation, and decreases the affinity for Raf (Spoerner, Herrmann et al. 2001, 
Spoerner, Wittinghofer et al. 2004). Likewise, calcium acetate was also found to bind 
this site on Ras (Buhrman, O′Connor et al. 2011). Since there is an allosteric 
communication pathway between the C-terminus and the switch regions of Ras, binding 
ligands to this site has the ability to perturb effector binding (Grant, McCammon et al. 
2010).  
 
Another ligand binding site on Ras lies on the core β-sheet between loop 2, helix 2 and 
loop 4 (Grant, Lukman et al. 2011). Several groups have shown that related sets of 
compounds bind to this pocket (Maurer, Garrenton et al. 2012, Sun, Burke et al. 2012, 
Shima, Yoshikawa et al. 2013). These compounds were shown to exert a variety of 
effects on nucleotide exchange and effector binding. The compounds found by Shima 
and co-workers also bind to several other Ras-like proteins. The last site on Ras that 
was shown to bind ligands is the switch 1 effector-binding loop, which interacts with 
Metal-Bis(2-picolyl)amine (BPA) (Rosnizeck, Spoerner et al. 2012) and also perturbs 
Raf interactions.  
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1.5 Dissertation Overview  
1.5.1 General Methods 
The second chapter presents the basic theory and methods used throughout the 
dissertation. This includes background on molecular mechanics, docking, signal 
processing and molecular dynamics (Chapter 2).  
 
1.5.2 Identification of Ligand Binding Sites on Receptor Ensembles 
The next chapter outlines a newly developed method whereby novel allosteric drug 
binding sites can be identified using probe ligands. The method describes the drug 
binding process as having both a deterministic and a stochastic component. The 
deterministic process is described by the laws of physics and chemistry (McCammon, 
Gelin et al. 1977) and the random process is described by statistics (Skolnick and Gao 
2013). 
 
The approach deviates from other methods by considering both the affinity and 
consistency of interactions (Cecchini, Kolb et al. 2004), and the rationale for using both 
is essentially two fold. The first reason being that there is a large error associated with 
calculating the binding energy between a ligand and a drug target. Second, even low-
affinity compounds can exert a biological function and therefore are of interest. To 
describe the physical and chemical aspects of ligand binding, we use well-known and 
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contemporary tools to calculate the ligand binding energy and to generate docked poses 
(Morris, Goodsell et al. 1998, Morris, Huey et al. 2009, Trott and Olson 2010). To 
quantify the stochastic aspects of the binding process, we use various tools from digital 
signal processing (Lathi 1998) and statistics (Rosner 2006). Collectively, this method 
determines the preference for a ligand-receptor pair and is named ligand binding 
specificity analysis (LIBSA) (Chapter 3).  
 
1.5.3 Probe Based Drug Discovery on a Flexible Ras Ensemble 
Using the LIBSA protocol, we screened a library of probe compounds against a library 
of receptor conformations to identify ligands that bind to novel sites on Ras. This study 
explores the ability of a diverse set of receptor conformations to bind probes at several 
pockets. Using this method, we identified two sites on Ras that bind ligands with high-
affinity and high preference: the switch 1 region and β-strands 1-3. These ligands were 
not always the compounds that exhibited the highest affinity, but the ones that also 
exhibited a high preference for a given binding site. This approach of simultaneously 
minimizing affinity and preference allows for unique sets of interactions to be formed, 
which will ideally favor binding at a single site.  
 
The computational hit (3) at switch 1 obtained a best preference score of 1.26 with a 
binding score of -10.1 kcal/mol. Binding at this location was stabilized by a hydrogen 
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bond with the backbone amide of I36, but most of the binding energy came from van 
der Waals contacts with P34, F28, I21, I24 and Y40. Similarly, binding on the core β-
sheet was mostly driven by van der Waals contacts with I36, Y64, M67 and L56, but 
E39, D54 and K5 all showed the ability to serve as hydrogen bonding partners. By 
incorporating receptor flexibility into the early stages of virtual screening, even 
transient receptor conformations can be identified as binding to small molecules. Most 
importantly, the docking experiments are based not on highest affinity poses but on the 
most frequently sampled poses, which we propose as a novel method for identifying 
computational hits (Chapter 4).  
 
1.5.4 Investigation of Andrographolide as an Anti-Ras Agent 
For several decades, a large number of pharmaceutical agents have been derived from 
natural products (Li and Vederas 2009). However, there has been a decline in the rate at 
which new drugs are brought to market (Scannell, Blanckley et al. 2012). To explore 
the potential of natural products to inhibit oncogenic Ras we considered the compound 
Andrographolide (Cava, Chan et al. 1962, Cava, Chan et al. 1965). It is a ladbane 
diterpenoid isolated from the plant Andrographis paniculata. It has been shown to be an 
anti-cancer and anti-inflammatory agent; however, the mechanism of action has never 
been fully elucidated (Hung, Hung et al. 2010, Lim, Chan et al. 2012).  
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Andrographolide has been previously shown to be an Erk MAPK inhibitor (Liang, Lin 
et al. 2008) and has been shown to inhibit G1 to S cell cycle progression (Jada, 
Matthews et al. 2008). To determine if Andrographolide interacts with Ras, we carried 
out simulations of oncogenic K-RasQ61H and performed ensemble docking and 
identified two putative binding modes on the switch regions. Subsequent MD 
simulations of the docked complexes showed that binding to the switch 1 region of Ras 
was preferred and resulted in a complex suggested to be resistant to exchange factor 
binding. Cell-based assays showed that treatment of cells with Andrographolide does 
inhibit the GTP loading and therefore activation of wild type Ras. However, 
Andrographolide failed to inhibit the GTP loading of oncogenic Ras over short time 
periods (6 hours) due to the fact that it is predominantly bound to GTP. It was only after 
allowing the intrinsic GTPase activity of mutant Ras to hydrolyze the γ-phosphate (72 
hours) was an Andrographolide derivative able to inhibit GTP loading of K-RasG12V. 
Therefore, Andrographolide can serve as a potential anti-cancer agent that is able to 
prevent the activation of oncogenic Ras by disrupting nucleotide exchange, which is 
required for activation of mutant Ras (Chapter 5). 
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1.5.5 Discussion 
Finally, the advantages of LIBSA are discussed along with it’s potential for the 
discovery of isoform and mutant specific Ras inhibitors. Additionally, the role of 
natural products and their ability to inhibit Ras nucleotide exchange are discussed 
(Chapter 6).  
 
1.6 Overall Hypothesis and Goal 
We hypothesize that there are allosteric sites on Ras that can be targeted by small 
molecules that selectively inhibit oncogenic K-Ras (Figure 1.6).  By using flexible 
receptors it is possible to develop compounds that selectively target individual Ras 
isoforms and mutants, which will result in more selective drugs.  
 
Figure 1.6 Proposed schematic of small molecule inhibition of Ras. 
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2 Materials and Methods 
2.1 Small Molecule Generation and Characterization 
Small molecule generation and characterization was performed with OpenBabel 
(O’Boyle, Banck et al. 2011) (www.openbabel.org). Ligands from NCI, ZINC, 
PubChem, MayBridge, ChemBridge, ChEBI, Bionet, DrugBank, eMolecules, and 
TimTec were downloaded as 2D structured-data format (SDF) compressed text files. 
The number of compounds downloaded totaled just over 30 million.   
 
To build 3D atomic coordinates from 2D coordinates, the Merck Molecular Force Field 
(MMFF94) developed by Halgren (Halgren 1996, Halgren 1996, Halgren 1996, Halgren 
1996, Halgren and Nachbar 1996) was utilized. Molecular interactions were comprised 
of quartic bond stretching, cubic angle bending, stretch-angle bending (approximation 
of Urey-Bradley), torsional twisting, a buffered 14-7 van der Waals interaction (Halgren 
1992), and a buffered Coulombic interaction. Non-bonded interactions were calculated 
using a cutoff method with critical values of 10 Å for van der Waals interactions and 20 
Å for electrostatic interactions (as implemented in OpenBabel version 2.3.1). The non-
bonded pair list was updated every 10 steps. Initially a rough 3D structure was 
generated and refined by 250 steps of steepest decent energy minimization with a 
tolerance of 1.0-4. This was followed by a rotamer search and 250 steps of conjugant 
gradient energy minimization with a tolerance of 1.0-6 to generate the final energy 
minimized structure.  
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The similarity between two ligands was assessed using the concept of a “molecular 
fingerprint”. The most common metric for comparing two fingerprints is the Tanimoto 
similarity index, which is analogous to the Jaccard similarity index. Each ligand is 
represented as a vector of Boolean values (a sequence of zeros and ones) where a one 
represents the presence of a chemical substructure. The chemical similarity between two 
ligands is then computed using Boolean logic and the Tanimoto index takes the form: 
T = andbitsorbits  
(2.1) 
The Tanimoto index is simply the ratio of the chemical features shared by both 
compounds to the total number of features found in both compounds and is bound 
between zero (no similarity) and one (maximum similarity). Ligand descriptors such as 
molecular weight, LogP, surface area, molar refractivity, etc. were also determined 
using OpenBabel.  
 
2.2 Site Directed Virtual Screening 
Virtual screening against well-defined regions of a protein was performed using 
AutoDock Vina (Trott and Olson 2010). Ligands were prepared for docking using either 
OpenBabel (O’Boyle, Banck et al. 2011) or AutoDock Tools (Morris, Huey et al. 2009). 
In both cases, atomic charges were determined using the method of Gasteiger-Marsili 
(Gasteiger and Marsili 1980). Ligands were flexible and receptors were rigid. All 
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screens were performed with an exhaustiveness parameter of 30 and the top 10 poses 
were returned.  
 
2.3 Global Docking 
Global docking or “blind docking” was used to identify ligand-binding sites on receptor 
conformations. All global docking experiments were performed with AutoDock version 
4.2 (Morris, Goodsell et al. 1998, Morris, Huey et al. 2009), which uses a physics based 
scoring function combined with a global and a local search algorithm to determine the 
best ligand-receptor orientation. The scoring function used in AutoDock is comprised of 
5 terms that account for van der Waals interactions (VDW), directional hydrogen bonds 
(Hbond), electrostatics (elec), torsional energy (tor), and solvation energy (sol), which 
were developed previously (Wesson and Eisenberg 1992).  
∆𝐺!"#$ = ∆𝐺!"# 𝐴!"𝑟!"!" − 𝐵!"𝑟!"!!,! + ∆𝐺!"#$% 𝐸 𝑡 𝐶!"𝑟!"!" − 𝐷!"𝑟!"!"!,!
+ ∆𝐺!"!# 𝑞!𝑞!𝜀 𝑟!" 𝑟(!")!,! + ∆𝐺!"#𝑁!"#
+ ∆𝐺!"# 𝑆!𝑉!𝑒 ! !!"!!!!!!,!  
(2.2) 
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The ∆𝐺 terms for each summation are weights determined empirically from linear 
regression analysis of known ligand-receptor complexes. The terms 𝐴!" and 𝐵!" are 
pairwise interaction potentials for the van der Walls contacts, and the terms 𝐶!" and 𝐷!" 
are pairwise interaction potentials for the hydrogen bonding interaction and the 𝐸 𝑡  
term is a directional weight based on the hydrogen bonding angle 𝑡. 𝑞! and 𝑞! are the 
charges on two atoms, 𝑟(!") is the distance between the atoms, and 𝜀 𝑟!"  is the 
dielectric constant. 𝑁!"# accounts for the entropy of the ligand and is proportional to the 
number of sp3 bonds. 𝑆! is an atom specific solvation term, 𝑉! is the fragmental volume 
of the atom, 𝑟!" is the distance to an adjacent atom, and σ is a constant. AutoDock 
produces two separate types of energies: docked energies and predicted free energies. 
During the docking process, the docked energies are used to find the best pose and are 
comprised of both the intramolecular and intermolecular energies. The predicted free 
energy is reported once the final docked pose is determined and includes the 
intermolecular free energy and the torsional free energy terms. 
 
By default, AutoDock 4.2 uses a hybrid Lamarckian Genetic Algorithm (LGA) that 
performs a global and a local search on the receptor. In AutoDock, genes correspond to 
variables that describe the orientation, translation, and conformation of the ligand 
relative to the receptor. In the global search, a probe ligand is randomly placed in the 
search box and scored. Then, a fraction of the probes are energy minimized using a 
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Solis & Wets algorithm. The top-binding pose is determined, and used to generate new 
ligand conformations. Docking experiments were parameterized to generate 256 docked 
poses using a ligand population size of 150, and the termination criterion for each 
docking run was 10,000 LGA generations or 109 energy evaluations. The search area 
was centered on the geometric center of the target and the box extended 10 Å beyond 
the protein edge.  
 
2.4 Molecular Dynamics Simulations 
2.4.1 Potential Energy Function (Force Field) 
All MD simulations were conducted with the nano-scale molecular dynamics package 
or NAMD (Phillips, Braun et al. 2005) using the CHARMM force field (MacKerell, 
Bashford et al. 1998, Vanommeslaeghe, Hatcher et al. 2010). The potential energy of 
the system (𝑈!"!#$) models bonded and non-bonded interactions between atoms and 
accounts for bond bending, bond stretching, bending of dihedral angles, Coulombic 
interactions, and van der Waals interactions (Equation 2.4.1.1).  
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𝑈!"!#$ =    𝑘! 𝑟!" − 𝑟! ! +  !"#$%  ! 𝑘! 𝜃! −   𝜃! !!"#$%&  !  
+   𝑘!(1+ cos 𝑛!ψ! − 𝜙!   𝑘! ψ! − 𝜙! !   , 𝑖𝑓  𝑛 > 0, 𝑖𝑓  𝑛 = 0!"!!"#$%  !  
+    𝑞!𝑞!4𝜋𝜀!𝑟!" + 4𝜀!" 𝜎!"𝑟!" !" − 𝜎!"𝑟!" !!!!!"#  !!!!!"#$"%&  !  
(2.3) 
For the 2-body spring potential, the energy between bonded atoms is modeled using 
Hooke’s Law where 𝑘! is the spring constant, 𝑟!" is the distance between the atoms, and 𝑟! is the equilibrium bond length. The 3-body angle energy term describes the deviation 
from an ideal angle formed by 3 bonded atoms where 𝑘! is the spring constant, 𝜃! is the 
measured angle and 𝜃! is the equilibrium angle. The 4-body torsion angle is commonly 
referred to as the dihedral angle. The 𝑛 term is the angle multiplicity, 𝜓 is the angle 
between the two planes, 𝜙 is the phase, and 𝑘! is a constant. In the Columbic term, the 
atomic charges are 𝑞! and 𝑞!, 𝑟!" is the distance between atoms and 𝜀! is the dielectric 
constant. In the Lennard-Jones term, 𝜀!" is the energy well depth, 𝑟!" is the distance 
between atoms, and 𝜎!" is the van der Waals radius. 
 
2.4.2 Equilibration and Production Simulation Protocols 
Initially, all missing hydrogen atoms from crystal structures were rebuilt using the 
CHARMM force field (MacKerell, Bashford et al. 1998, Mackerell 2004, 
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Vanommeslaeghe, Hatcher et al. 2010) force field and VMD (Humphrey, Dalke et al. 
1996). Equilibration was accomplished by first subjecting the system to 20,000 steps of 
conjugate gradient energy minimization with positional restraints applied to all non-
water heavy atoms, followed by heating the system to the target temperature of 310 K. 
This was followed by an equilibration simulation with a harmonic restraint with a force 
constant of 4 kcal/(mol!Å2) applied to all protein backbone atoms. The force constant 
was linearly decreased to zero over a period of 200 picoseconds. Non-bonded 
interactions were calculated using a switching distance of 10 Å, a cutoff distance of 12 
Å, a pair-list update distance of 14 Å, and an integration time step of 1 femtosecond. 
Each production trajectory was started from an equilibrated system and seeded with a 
random initial velocity. Each trajectory was carried out in the isothermal-isobaric 
ensemble using Langevin dynamics to control the system temperature and a hybrid 
Nose-Hoover Langevin piston method to maintain a constant pressure of 1.01325 bar. 
Production runs were carried out using a non-bonded switching distance of 8.5 Å, a 
cutoff distance of 10 Å, a pair-list update distance of 12 Å and an integration time step 
of 2 femtoseconds using SHAKE to constrain all bond angles involving hydrogen. The 
long-range electrostatic interactions were calculated using the particle mesh Ewald 
method (Darden, York et al. 1993). Trajectory snapshots were saved every picosecond. 
Analysis and visualization was performed using VMD and R with the Bio3D library 
(Humphrey, Dalke et al. 1996, Grant, Rodrigues et al. 2006, 2008).   
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2.5 Generation of Ras Mutants Using Molecular Dynamics 
We conducted classical all-atom MD simulation of 8 Ras systems (WT, G12V, Q61L, 
and Q61H K-Ras and H-Ras) using the CHARMM27 force field and version 2.7b of 
NAMD (MacKerell, Bashford et al. 1998, Phillips, Braun et al. 2005). The wild type H-
Ras system was started from PDB 1QRA, and wild type K-Ras was generated from K-
RasQ61H (PDB 3GFT) using VMD. H-RasG12V and H-RasQ61L were constructed by 
mutation of wild type H-Ras. The K-RasG12V and K-RasQ61L systems were generated 
by taking an MD derived conformer (taken at time point 300 ns) and mutating Gly12 to 
valine and Gln61 to leucine. H-RasQ61H was started from PDB 621P. 
 
2.6 Principal Component Analysis (PCA) 
Principal component analysis is a widely used technique that reduces the dimensionality 
of large data sets based on the variance of the data. Using a linear transformation, PCA 
takes a dataset and computes the variance of the different variables and orders the data 
in descending order. Therefore, data sets that deviate significantly from the mean can be 
identified. The first principal component (PC1) contains the most variance; the second 
principal component (PC2) contains the second highest variance and so forth. The use 
of PCs to analyze large macromolecules is well established and has been shown to be a 
reliable method for analysis of proteins (Wold, Esbensen et al. 1987, Hess 2000, 
Papaleo, Mereghetti et al. 2009, Abdi and Williams 2010).  
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2.7 Root Mean Square Deviation 
The root mean square deviation (RMSD) of overlaid atomic coordinates is a common 
way to quantify the average distance between two structures. Using two points denoted 𝑎! and 𝑏!, where 𝑁 is the total number of pairs, the RMSD is computed as follows: 
𝑅𝑀𝑆𝐷 =    1𝑁 𝑎! − 𝑏! !!    (2.4) 
 
2.8 Digital Signal Processing 
2.8.1 Fourier and Inverse Fourier Transforms 
The Fourier transform maps a signal from its time domain (𝑓) into its frequency domain 
(𝑓) (Lathi 1998). The time domain is defined to be a real valued and integrable function 
whereas the frequency spectrum is a complex, integrable function with the real and 
imaginary values describing the magnitude and phase of the spectrum.  The forward 
Fourier Transform is defined as follows: 
𝑓(𝜉) =      𝑓(𝑥)𝑒!!!"#$!!! 𝑑𝑥 (2.5) 
 
In equation 2.8.1.1 𝜉 is any real number, 𝑖 is the square root of -1, and 𝑥 is the time 
domain variable. The inverse Fourier transform is defined as follows: 
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𝑓(𝑥) =      𝑓(𝜉)𝑒!!"#$!!! 𝑑𝜉 (2.6) 
Together the functions 𝑓 and 𝑓 are called the Fourier transform pair, and one can be 
obtained from the other.  
 
2.8.2 Noise Reduction in Fourier (Frequency) Space 
In general, noise reduction is performed in frequency space and is accomplished by the 
use of several different filtering algorithms (Butterworth, Chebyshev, Elliptical etc), 
which can remove either low or high frequency noise. For example, a high-pass filter 
scales down the amplitude of peaks with a frequency lower than that of the cutoff value. 
Likewise, a low-pass filter scales down the amplitude of peaks with a frequency higher 
than the cutoff value. The extent and manner of the amplitude reduction is a function of 
the type of filter used.  
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3 LIBSA – A Method For the Determination of Ligand-Binding Preference to 
Allosteric Sites on Receptor Ensembles 
This chapter is based upon, “Hocker, H.J.; Rambahal R.; Gorfe A.A. LIBSA – A 
method for the determination of ligand binding preference to allosteric sites on receptor 
ensembles” J. Chem. Inf. Model. 2014, in press.  
 
3.1 Introduction 
In recent decades, the number of drugs brought to market has been declining and new 
low-cost methods for drug discovery are needed (Scannell, Blanckley et al. 2012). 
While virtual screening is able to reduce the total number of ligands that need to be 
synthesized and screened experimentally (Shima, Yoshikawa et al. 2013), it requires 
prior knowledge of the target site (Schneider 2010, Yuriev, Agostino et al. 2011). 
However, some of the most effective compounds on the market bind to allosteric sites 
(Christopoulos 2002), and these sites are not always apparent in average structures from 
X-ray crystallography or NMR (Schames, Henchman et al. 2004). There are several 
computational techniques for binding site identification, including FTMap (Brenke, 
Kozakov et al. 2009), blind docking (Grant, Lukman et al. 2011, Hocker, Cho et al. 
2013), solvent mapping (Verkhivker, Bouzida et al. 2003), and other simulation-based 
methods (Bakan, Nevins et al. 2012). Once the sites are determined, virtual screening 
(VS) can be performed to find small-molecule ligands that have the potential to become 
hits (Warren, Andrews et al. 2005). Typically, VS is followed by experimental assays of 
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the highest affinity compounds. Although the application of any of these methods to one 
or a few conformations of a receptor is fairly straight forward, there is no simple way to 
find a consensus-binding site on a large number of structures or to prioritize hits by 
preference to a particular binding site. This is important because ligand-receptor affinity 
is a property of an ensemble (Benedix, Becker et al. 2009) and therefore incorporation 
of target flexibility is crucial for success (Lin, Perryman et al. 2002). Moreover, almost 
all docking methods rank ligands based on predicted binding affinities (Kitchen, 
Decornez et al. 2004), despite examples of low-affinity hits having led to potent bio-
active compounds (Barreiro, Kim et al. 2007). We have developed a technique called 
LIgand Binding Specificity Analysis (LIBSA) that quantifies (and prioritizes by) 
pocket-specificity following a search for allosteric ligand binding sites over an 
ensemble of receptor conformations.  
 
LIBSA uses a small molecule or fragment as a probe to search for allosteric binding 
sites on the surface of a protein. This can be done by popular docking programs such as 
Autodock (Morris, Huey et al. 2009), which in principle are capable of finding the 
correct binding site for the right ligand when the search area covers the entire protein 
surface (Hetenyi and Vanderspoel 2006, Grant, Lukman et al. 2011). However, this 
approach is likely to yield random docked poses. These poses typically have a low 
probability of occurring and thus should be filtered out. We introduce two techniques to 
remove such poses: a high-pass filter (Butterworth 1930) and an algorithm that filters 
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out ligand poses based on their frequency of occurrence. The latter favors poses with 
high affinity and the high-pass filter (Butterworth 1930) removes false-positive hits by 
scaling down ligand-receptor contacts that fall below a threshold value. We then use a 
signal-to-noise ratio (SNR) (Vary and Eurasip 1985), defined as the relative frequency 
of a ligand contacting a particular region of the protein versus all other regions, to 
quantify binding specificity. In sum, the general procedure of LIBSA entails probing a 
receptor conformation with a ligand, determining the frequency of the different protein-
ligand contacts, filtering out random poses, and then quantifying the consistency of 
binding with the SNR (Figure 3.1). 
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Figure 3.1 Schematic outline of the LIBSA protocol for the determination of ligand 
binding preference to allosteric sites on a single or ensemble of receptor conformations. 
(Left) Workflow of LIBSA. (Right, top to bottom) Optional preprocessing to group 
protein conformers based on clustering or other methods; “blind docked” of probe 
ligands (cyan sphere) on multiple receptor conformers; contact spectrum generated from 
the probe ligands (red = noise; green = signal, the filtered spectrum is also shown as 
inset); ranking of ligands by signal-to-noise ration (SNR) where site A represents a 
hypothetical pocket corresponding to the green peaks while B and C are sites of non-
specific binding.  
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As an initial test, we used LIBSA to correctly identify the active site on a set of 
receptors co-crystalized with small molecule drugs, including a group of kinase 
domains (Nagar, Bornmann et al. 2002), nuclear receptors (Shiau, Barstad et al. 1998, 
Gangloff, Ruff et al. 2001, Bruning, Parent et al. 2010), the β2AR (Rasmussen, DeVree 
et al. 2011), HIV-protease (Chen, Li et al. 1994), and K-Ras (Maurer, Garrenton et al. 
2012, Sun, Burke et al. 2012). We then applied LIBSA to rank four related compounds 
by binding site preference when docked onto an ensemble of 148 experimental and 
simulated Ras structures.  
 
3.2 Materials and Methods 
3.2.1 Generating a Library of Receptor Conformers for Docking 
We applied LIBSA on two sets of structural ensembles. The first involved 10 protein-
ligand complexes from the Protein Data Bank (PDB) representing five different protein 
families (G-proteins, G-protein coupled receptors, kinases, nuclear receptors, and 
proteases). In each case, the co-crystalized ligand was removed and used as a probe for 
blind docking to search for the binding site on the co-crystal conformation (Table 3.1) 
and, when available, the corresponding apo structure (Table 3.2). The second ensemble 
containing 148 wild type and mutant H- and K-Ras conformers derived from molecular 
dynamics (MD) simulations (80), crystallography (66) and nuclear magnetic resonance 
(2 averaged and energy-minimized structures). The MD simulations were conducted as 
described in Appendix A and representative structures were identified as follows. 10ps-
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separated snapshots from trajectories were clustered using Cα atom positions with the 
leader-RMSD-based algorithm implemented in Wordom (Seeber, Cecchini et al. 2007). 
The RMSD cutoff for clustering ranged from 1.3 to 1.8 Å so that the top 10 clusters 
contained 92-99% of the conformations in each trajectory. The resulting 80 cluster 
centroids were taken as representative conformations of the large phase space sampled 
by the simulations. For an additional and more global characterization of the ensemble, 
we re-grouped the structures into five clusters in principal component (PC) space with 
the K-means algorithm (Ihaka and Gentleman 1996).  
  
3.2.2 Molecular Docking 
The proteins and ligands were prepared for docking by first removing ions and water 
molecules and building missing protein atoms using the CHARMM27 force field 
(MacKerell, Bashford et al. 1998) and VMD (Humphrey, Dalke et al. 1996); missing 
nucleotide hydrogen atoms were built using AutoDock Tools (Morris, Huey et al. 2009) 
or OpenBabel (O’Boyle, Banck et al. 2011). The structure of ligands Andrographolide 
(AGP), 3,19-(2-bromobenzylidene) andrographolide (SRJ09), 3,19-(3-
bromobenzylidene) andrographolide (SRJ10) and 3,19-(3-chloro-4-fluorobenzylidene) 
andrographolide (SRJ23) (Hocker, Cho et al. 2013) were prepared using the CHARMM 
generalized force field (CGenFF36) (Vanommeslaeghe, Hatcher et al. 2010), as 
described before (Hocker, Cho et al. 2013). Then, non-polar hydrogen atoms were 
condensed into their respective heavy atoms and atomic charges were assigned using 
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the Gasteiger-Marsili method (Gasteiger and Marsili 1980). “Blind docking” (Hetenyi 
and Vanderspoel 2006) was carried out with AutoDock 4.2 (Morris, Huey et al. 2009) 
with the aid of the AutoDock tools (ADT) package (Morris, Huey et al. 2009), keeping 
the ligand flexible and the receptor rigid. The search space was a cubic box covering the 
entire surface and centered on the geometric center of the protein, extending 10 Å 
beyond the protein edge in each direction. The termination criterion for each docking 
run was set to be either 10,000 LGA generations or 109 energy evaluations, which ever 
comes first. The genetic algorithm (GA) population size and the Solis & Wets local 
search probability were optimized for each protein depending on the volume of the 
search area, the accessibility of the pocket and the number of rotatable bonds in the 
ligand. Additional details of the docking parameters are listed in Tables 3.1 and 3.2. 
  
3.2.3 Affinity Filtering: Noise Reduction Using Docking Scores 
It is well known that ranking by predicted affinity is a major source of false positives 
(error of ~2 kcal/mol (Morris, Huey et al. 2009)), and currently there is no simple way 
to identify potential hits with low predicted affinity. Therefore, we have developed an 
approach that favors binding consistency over affinity by putting more weight on the 
frequency of occurrence of a particular docking score rather than the magnitude of the 
score. A key concept behind affinity filtering is that docking scores can be used as a 
metric for pose uniqueness and not just ranking. The steps for performing the filtering 
are as follows: (i) generate a histogram of the binding scores, which we refer to as 
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affinity spectrum, from the AutoDock DLG file (in kcal/mol). (Since AutoDock gives 
the scores with a precision out to the hundredth decimal we used a relatively fine 
binning width of 0.05 kcal/mol.) (ii) Identify the peaks that represent frequently 
sampled affinity space based on a simple cutoff relative to the maximum value within 
each spectrum. We found that a threshold of 40% of the maximum peak value yields the 
best compromise between elimination of false positives and retention of alternative 
poses at a given site. We therefore collected all peaks whose height is ≥40% of the 
maximum peak height and referred to them as explicit peaks.  (iii) To account for the 
fact that scoring functions are error prone, we added all peaks whose AutoDock score is 
within a certain percentage of that of the explicit peaks, which we call auxiliary peaks 
(i.e., peaks in neighboring bins each side of the explicit peaks). For example, using a 
sampling window of 1% (as used throughout this chapter) and a hypothetical explicit 
peak with an average energy score of -10.0 kcal/mol in a spectrum of bin width 0.05 
kcal/mol, we include the peaks in the first 2 bins each side of the explicit peak 
| !!".!×!.!"   |  !.!" = 2 . (iv) Write out the structures that gave rise to the explicit and 
auxiliary peaks, this requires keeping track of each docked conformation in step (i).   
 
This procedure effectively eliminates low frequency high affinity poses while assigning 
more weight on the high frequency high affinity poses. Moreover, poses that are similar 
in affinity to the high frequency ones but appear less frequently can be captured through 
the incorporation of auxiliary peaks around the explicit peaks.  
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3.2.4 Binding Site Identification and Scoring with SNR 
The affinity filtering described above identifies docked poses that are well sampled in 
affinity space irrespective of their binding site on the receptor. To identify a ligand-
binding site, we use histograms of the frequency with which a ligand contacts residues 
on the receptor, followed by an analysis of the signal-to-noise ratio (SNR, see below). 
This entails two simple steps. First, generate a histogram of residue contact frequencies 
by counting the number of times any heavy atom of a residue lies within 4.0 Å of any 
ligand heavy atom during repeated docking runs. In this histogram, which we refer to as 
contact spectrum, each bin corresponds to a single residue, and for each ligand there can 
be as many contact spectra as there are receptor conformations. Second, define a surface 
patch of interest (e.g., from the dominant peaks in the contact spectrum or from prior 
knowledge about the biochemical/structural features of the protein).  Then, the binding 
preference of a ligand to the patch is quantified by SNR (eq. 1), where signal refers to 
peaks that lie within the binding patch and noise denotes the peaks that lie outside the 
binding patch:  
𝑆𝑁𝑅 =    log!" !!"#$% !!!!"#$%& !!        (3.1) 
Here 𝑢! refers to the peak height at residue 𝑖 and is indexed over all the residues that lie 
within the binding patch (total number = Nsignal) and 𝑢! is the peak height at residue 𝑗 
indexed over all the residues that lie outside the binding patch (total number = Nnoise). 
Since the function is divergent when the noise term is zero we arbitrarily set the noise 
floor to 0.0001; SNR is set to 0.0 when the signal is zero. 
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This approach allows for scanning the protein surface for allosteric ligand binding sites, 
ranking ligands by their preference for a given site or establishing threshold SNR values 
below which binding could be deemed non-specific (see Results and Discussion). One 
caveat is that this procedure cannot be easily automated for receptors whose ligand 
binding site(s) is not well defined. One solution could be to build a series of patches 
over the entire surface and compare the final SNRs, or use prior knowledge about the 
target including interaction sites or sites of posttranslational modification (e.g., 
acetylation, phosphorylation, ubiquitination).  
 
3.2.5 High-pass Filter: Noise Reduction Based on Contact Frequency 
Concepts from digital signal processing such as high-pass filters can be used to directly 
remove docking noise from a contact spectrum by treating it as a discrete signal. Here 
we use the Butterworth filter (Butterworth 1930), though other types of filters could 
also be used. A 5th order Butterworth high-pass filter with a critical value equal to the 
Golden ratio conjugate (Dunlap 1997, Boroden 2008) (or golden section taken as 
0.618), efficiently removes less frequent contact signals and allows for predominant 
peaks to be more easily identified. The formulation we used is as follows:  𝐻 𝑢 =    !!! !!!!! !           (3.2) 
where 𝑢! is the golden section, 𝑢 is the input spectrum, and 𝑛 is 5. Note that in this 
analysis, the contact spectra should all be internally normalized to the maximum value 
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in order to use a consistent cutoff across the data. Moreover, using an appropriate cutoff 
is crucial because, if the cutoff value is set too low, the noise will be amplified and if it 
is set too high the signal is not properly enhanced. A contact spectrum can be 
constructed from a single ligand-receptor pair or by combining the results from multiple 
ligand-receptor pairs into a single histogram. In either case, the general procedure 
involves generating a contact spectrum as described in the previous section, applying 
the high-pass filter and computing the SNR. 
 
Although high-pass and affinity filters serve somewhat different purposes and operate 
on different spectrum type, their end result is the same: remove docking noise. 
Therefore, either can be used in many situations. One advantage of applying a high-pass 
filter on contact spectra is that it makes no assumption about the relationship between 
affinity and ligand-binding residues (i.e., affinity is completely removed from the post-
docking analysis).  
 
3.2.6 Consensus Ligand Binding Site Identification with Ensemble SNR 
In the context of docking, the most notable difference between NMR/X-ray 
crystallographic and MD data is the number of structures involved. The former is 
typically one or several to dozens while the latter can be in the millions, which 
complicates the search for emergent binding sites. Ensemble SNR, which is a simple 
extension of the procedures discussed above, can help tackle this problem. The key here 
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is to cluster the receptor conformations into N groups (denoted α, β, γ, δ in Figure 1) 
based on either global or local structural features, such as solvent accessible surface 
area, principal components, pocket volume, backbone RMSD etc. Then a single contact 
spectrum can be built by averaging the data from all members of a cluster (e.g., α), 
which can then be used to compute SNR for use in consensus-binding site 
identification. Thus, this approach combines results from multiple, independent docking 
experiments and produces a single number that describes how frequently a ligand binds 
to a given region. Such an ensemble-averaged SNR can improve prediction as the 
results are not contingent upon a single structure but on multiple structures (Lin, 
Perryman et al. 2002, Amaro, Baron et al. 2008). Its major drawback lies in the 
assumption that the pocket is present on most if not all of the structures within a cluster. 
It is thus prudent to first examine individual SNRs to ensure that the desired pocket is 
present in the majority of the cluster members before proceeding to generating an 
ensemble-averaged SNR. 
 
3.3 Results and Discussion 
3.3.1 Validation of LIBSA 
3.3.1.1 Blind Re-docking of Co-crystalized Ligands 
A set of 10 protein-ligand complexes was used to assess the ability of the method to 
reliably identify known ligand binding sites. Table 3.1 shows that calculation of SNR 
from the raw docking data yields SNR values equal to or greater than 1.0 for each 
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system. While SNR > 0.0 (see eq. 3.2) can be regarded as a successful identification of 
the binding site, SNR ≥ 1.0 is even better because this means that there are at least 10-
times more hits in the active site than elsewhere on the protein. Importantly, preceding 
the SNR calculations by affinity filtering led to an even larger (i.e., better) SNR for half 
of the test cases. 
 
Many docking algorithms including AutoDock are sensitive to the total number of 
rotatable bonds on the ligand (Chang, Ayeni et al. 2010). It is therefore expected that 
the number of flexible torsions will likewise affect post-processing by SNR. Indeed, the 
smallest SNR was found for Indinavir, which has the largest number of active torsions 
(14). This is likely because it overwhelmed the search algorithm in AutoDock, as 
suggested by the dramatically larger SNR (3.85) obtained when the ligand is docked 
with all its torsions fixed to their crystal structure value (see Indinavir* in Table 3.1 and 
Figure 3.2a). 
 
 
 
 
 
 
41 
Table 3.1 Performance of LIBSA on known protein-ligand complexes.* 
Ligand Receptor PDB ID Box Vol. 
(Å3) 
Pop (S&W) # Lig 
Tors 
RMSD 
(Å) 
SNR 
       No 
Filter 
Affinity 
Filter 
Nilotinib p38 MAPK 3GP0 2.1e5 225 (0.25) 7 0.72 1.12 1.15 
Gleevec c-Abl Kin. 1IEP 1.9e5 225 (0.25) 7 1.34 1.42 1.43 
Tamoxifen ERα 3ERT 2.2e5 150 (0.10) 10 1.46 2.06 3.75 
Raloxifene ERα 2QXS 2.1e5 150 (0.10) 9 0.95 1.50 1.76 
Estradiol ERα 1QKT 2.1e5 150 (0.10) 2 1.01 3.64 3.64 
BI-167107 β2AR 3SN6 2.5e5 225 (0.25) 8 1.48 1.15 1.07 
Indinavir HIV Pr.  1HSG 1.3e5 225 (0.25) 14 1.41 0.96 0.94 
BZI K-Ras 4DSU 1.3e5 150 (0.10) 0 0.94 1.10 3.48 
0QV K-Ras 4EPW 1.1e5 150 (0.10) 3 0.74 1.17 3.54 
0QW K-Ras 4EPT 1.0e5 150 (0.10) 3 0.71 1.24 1.74 
* Selected protein-ligand complexes from the protein databank were used to illustrate 
the ability of LIBSA to identify the active site and ligand pose. SNR values were 
calculated with the affinity filter and without any filter. The AutoDock ligand 
population size (Pop), probability of performing a Solis & Wets (S&W) local energy 
minimization, rotatable bonds in the ligand (Lig. Tors), volume of the search box, and 
the lowest docked RMSD relative to the crystal pose are listed. Kin. = kinase, Pr. = 
protease.  
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Therefore, the complexity of the probe to be used in LIBSA will depend on the 
capability of the program used for docking. Similarly, convergence of SNR should 
depend on the number of docked poses generated, as shown by the profile of the SNR 
calculated from contact spectra with 5-256 docked poses (Figure 3.2a). Excluding 
estradiol and Indinavir* whose SNR was invariant, convergence was achieved (Figure 
3.2a) and the variance plateaued after about 100 runs, with the coefficient of variation 
being 0.01-0.03 for the remaining 100-256 runs.  
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Figure 3.2 Global docking followed by Signal to Noise Ratio (SNR) analysis for our 
test cases. (a) Chemical structure of ligands used to evaluate the performance of LIBSA 
on known protein-ligand complexes. (b) Convergence of SNR during 5-256 docking 
runs to the value reported in “No filter” column of Table 3.1. (c) The cumulative 
variance of SNR decreases as the number of poses increases. Estradiol, which has only 
2 rotatable bonds, and Indinavir*, whose torsions were fixed, targeted a single site and 
therefore yielded a constant SNR regardless of the number of docked poses used. 
BZI=benzimidazole, 0QV=(4-hydroxypiperidin-1-yl)(1H-indol-3-yl)methanethione, 
0QW=(2-hydroxyphenyl)(pyrrolidin-1-yl)methanethione.  
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Overall, LIBSA identified the right binding site (Table 3.1 and Figure 3.2) and 
recovered the correct ligand pose with reasonably small root mean square deviations 
(RMSD) from the crystal poses (Table 3.1). Moreover, affinity filtering increased the 
SNR for half of the ligand-protein pairs without affecting the rest, supporting our 
expectation that low probability poses are characteristic of docking noise. 
 
3.3.1.2 Blind Docking of Known Ligands on Apo Structures 
To examine if LIBSA could identify the correct binding site on structures solved 
without the probe ligand, we blind-docked estradiol on ERα, Gleevec and Nilotinib on 
p38 MAPK, BI-167107 on β2AR, and Tamoxifen and Raloxifene on ERα. (Indinavir 
was excluded due to its large number of rotatable bonds, as discussed in the previous 
section.) Of these, visual analysis suggested that the ligand-binding pocket on the apo 
structure of p38 is open and appears suitable for binding, whereas that of ERα is small 
and β2AR’s is closed. As shown in Table 3.2, LIBSA predicted a positive binding 
preference of ~0.7 for both p38 ligands and 3.61 for the small ligand estradiol on ERα. 
In contrast, the SNR is negative when the pocket is closed (β2AR) or the ligand is too 
large to fit in the pocket (Tamoxifen/Raloxifene on ERα). This result provides 
additional evidence that LIBSA can discriminate between favorable and unfavorable 
binding. 
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For a further and more stringent test we docked three ligands that were solved with K-
Ras (0QW, 0QV and BZI) onto two X-ray and one MD apo structures of the 
homologous protein H-Ras. The H-Ras structures were chosen because they display a 
pocket similar to that seen in the ligand-bound K-Ras. LIBSA yielded SNR values of 
~0.6-1.6 for these pairs (Table 3.2), showing that our tools are robust and applicable to 
diverse problems. Finally, cross docking of the chemically somewhat similar Gleevec 
and Nilotinib (Tanimoto coefficient of 0.6 (Manley, Stiefl et al. 2010)) on c-Abl and 
p38 kinases resulted in SNR = 1.05 for both. Thus LIBSA was able to recognize the 
potential of ligands with similar chemical signature to have similar binding profiles.  
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Table 3.2 LIBSA analysis of test ligands docked onto crystal and MD-derived apo 
structures. 
Ligand Receptor Structure Box Vol. 
(Å3) 
Pop 
(S&W) 
#Lig. 
Tors 
SNR 
Docking onto an apo structure with open or semi-open binding site 
Estradiol ERα 2B23 1.5e5 150 (0.10) 2 3.61 
0QW H-Ras 2CL0, 2RGB, MD 1.1-1.2e5 150 (0.10) 3 1.11, 1.03, 0.55 
BZI H-Ras 2CL0, 2RGB, MD 1.1-1.2e5 150 (0.10) 0 1.05, 1.00, 1.58 
0QV H-Ras 2CL0, 2RGB, MD 1.1-1.2e5 150 (0.10) 3 0.87, 0.72, 0.86 
Gleevec p38 MAPK 1WFC 2.5e5 225 (0.25) 7 0.75 
Nilotinib p38 MAPK 1WFC 2.5e5 225 (0.25) 7 0.71 
Docking onto an apo structure with occluded or small binding pocket 
BI1667107 β2AR 2R4S 1.9e6 225 (0.25) 8 -0.04 
Raloxifene ERα 2B23 1.5e5 150 (0.10) 9 -0.16 
Tamoxifen ERα 2B23 1.5e5 150 (0.10) 10 -0.17 
Global cross docking 
Nilotinib c-Abl Kin. 1IEP 1.9e5 225 (0.25) 7 1.05 
Gleevec p38 MAPK 3GP0 2.1e5 225 (0.25) 7 1.05 
Because the available Ras ligands are reportedly non-specific for the highly 
homologous Ras isoforms (Maurer, Garrenton et al. 2012, Sun, Burke et al. 2012), for a 
stringent test of LIBSA we docked ligands solved with the K-Ras isoform on two PDB 
and an MD apo structure of H-Ras. These structures were chosen because they posses a 
visually discernible pocket that is similar to that in the ligand-bound K-Ras PDB 
structures 4DSU, 4EPT or 4EPW.  
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In sum, LIBSA was able to correctly identify binding sites on apo structures derived 
from crystallography or MD (Table 3.2), though the success rate is somewhat smaller 
than in “re-docking”  (Table 3.1). Taken together, these results highlight the potential of 
global docking combined with our analytic tools to numerically describe ligand-binding 
preference, identify putative binding sites, and filter out off target poses.  
 
3.3.2 Ranking Ligands and Classifying Receptor Conformations by Binding 
Specificity 
Here we used an ensemble of 148 Ras conformers (see Methods) and four ligands from 
our previous work (AGP, SRJ09, SRJ10 and SRJ23) (Hocker, Cho et al. 2013) to 
illustrate how chemically similar yet pharmacologically different (Jada, Matthews et al. 
2008, Hocker, Cho et al. 2013) compounds may exhibit distinct pocket and 
conformation preferences when analyzed by LIBSA. Focusing only on four previously 
described sites (Grant, Lukman et al. 2011), we calculated SNR after removing non-
specific hits by affinity filtering. The results (Table 3.3) show that the four compounds 
predominantly target p1 or p3a (SNR>0.0) and rarely visit pockets 2 and p3b. In fact, 
SNR ≥1.0 was obtained only for p1 and p3a.  
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Table 3.3 LIBSA-predicted ensemble-average binding preferences of AGP and its 
derivatives for specific pockets on Ras. 
Ligand Ras Cluster SNR 
  p1 p2 p3a p3b 
 1 -2.56 -2.24 3.80 0.53 
 2 0.83 0.13 0.63 -0.13 
AGP 3 -1.27 -0.39 1.66 0.36 
 4 1.59 0.12 -3.54 -3.89 
 5 -1.39 -0.14 1.31 -0.22 
 1 -1.70 -2.25 1.67 0.68 
 2 1.07 0.03 -0.02 0.40 
SRJ09 3 -0.30 -0.26 1.10 0.75 
 4 1.52 0.15 -4.17 -3.91 
 5 0.36 -0.43 0.73 0.44 
 1 -1.60 -1.95 2.65 0.91 
 2 1.15 0.13 -0.22 0.13 
SRJ10 3 -0.40 -0.23 1.20 0.58 
 4 1.54 0.10 -3.81 -3.65 
 5 0.33 -0.29 0.70 0.13 
 1 -1.81 -2.04 1.75 0.82 
 2 1.47 0.29 -0.39 -0.29 
SRJ23 3 -0.19 -0.06 0.98 -0.01 
 4 1.60 0.16 -5.00 -5.51 
 5 0.28 -0.26 0.77 -1.14 
Receptor clusters were defined using K-means clustering based on principal 
components (see text). SNR scores were calculated after applying high-pass filter to the 
raw data. Based on the definition of SNR (eq. 2) and the benchmark data in Tables 3.1 
and 3.2, SNR>1.0 (highlighted in bold) implies high preference for a given pocket, 
0<SNR<1.0 (bold-italic) moderate preference and SNR<0.0 not favored.  
 
 
 
 
 
 
50 
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Figure 3.3 LIBSA of four highly related ligands docked onto an ensemble of Ras 
conformers. (a) Chemical structure of AGP, SRJ09, SRJ10, and SRJ23. (b) Distribution 
of the hits with SNR >1.0 at sites p1, p2, p3a and p3b, showing preference of the SRJ 
ligands for p1 (~70-80%) and AGP for p3a (58%). (c) PC projection of the 148 Ras 
conformations used for docking (clustered into 5 groups based on their first two PCs), 
as well as conformers from a trajectory of K-RasQ61H bound to SRJ23 at p1 pocket 
(gray shade). Clusters 2 and 4, which overlay well with conformers of SRJ23-bound K-
RasQ61H, bind ligands at p1 according to the ensemble SNRs shown in Figure 3.4.  
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To check if AGP and its derivatives preferentially (SNR ≥1.0) hit a given site on the 
same set of conformers, we used the Jaccard similarity coefficient, 𝐽, defined here as the 
ratio between the number of conformers targeted by both ligands a and b (na,b) and the 
total number of conformers targeted by either ligand (na + nb): 𝐽 =      !!,!!!!!!.          (3.3)  
 
Table 3.4 shows that the rather similar SRJ compounds target the same pocket on the 
same set conformers about 50% of the time on average, whereas the chemically more 
divergent AGP has less in common with the SRJs in terms of both its pocket and 
conformation preference. This is consistent with our observation from cross docking on 
Abl and p38, and highlights yet another utility of LIBSA. 
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Table 3.4 Ligand binding similarity among MD-derived Ras conformers. 
 
 
 
The data represent quantification of the ability of closely related ligand pairs to target a 
given pocket on the same set of Ras conformers, calculated as the ratio between the 
number of Ras conformers targeted by both ligands and the total number of conformers 
targeted by either ligand. Upper triangle: pocket p1, lower triangle: p3a. 
 
 
 
 
 
 
 
 
 
 
 
 AGP SRJ09 SRJ10 SRJ23 
AGP  0.40(10/25) 0.41(11/27) 0.41(13/32) 
SRJ09 0.11(3/27)  0.56(14/25) 0.48(15/31) 
SRJ10 0.11(3/27) 1.0(5/5)  0.49(16/33) 
SRJ23 0.11(3/27) 0.43(3/7) 0.43(3/7)  
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As mentioned earlier, affinity filtering can be replaced or complemented by a high-pass 
digital filter if groups of structurally related receptor conformations exhibit similar 
tendencies to bind small molecules. We thus divided the Ras conformers into 5 groups 
with the K-means clustering using Euclidean distances based on principal components, 
analyzed each group separately with the high-pass filter and SNR, and compared the 
results. This led to the following observations (Figures 3.3 & 3.4 and Table 3.4): (i) the 
SRJ compounds have a preference (SNR ≥ 1.0) for p1 in clusters 2 and 4 and p3a in 
clusters 1 and 3. (ii) In contrast, AGP favors p1 only in cluster 4 and p3a in clusters 1, 
3, and 5. (iii) Cluster 5 shows no tendency to bind any of the SRJ compounds. Thus, a 
combination of structure clustering, high-pass filtering and SNR calculation can isolate 
reasonably well a group of receptor conformers that preferentially bind a similar set of 
ligands.  
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Figure 3.4 High-pass filtered ensemble contact spectra derived from blind-docking the 
probe SRJ23 on multiple Ras conformers (normalized by the largest score). (a) The 
single dominant peak in the ensemble-averaged contact spectra of clusters 2 and 4 
yielded a p1 SNR > 1.0. (b) The three large peaks in the ensemble-averaged contact 
spectrum of cluster 1 yielded a p3a SNR > 1.0. (c) The more cluttered spectra for 
clusters 3 and 5 yielded insignificant SNRs. Insets in (a) and (b) illustrate binding to 
pockets p1 and p3a using the surface of representative Ras structures colored by contact 
spectrum (red-to-back: high to low binding probability).  
 
It should be noted that the ensemble contact spectrum used here does not represent a 
single conformation but multiple receptor conformations in tandem (see Methods). 
Additionally, application of the high-pass filter does not directly correlate with the 
simple inclusion or exclusion of docked poses, as does affinity filtering. As a result, the 
scaled spectrum cannot be represented by a single structure. That said, the receptor 
conformations identified by a high-pass filter plus SNR as favoring p1 binding (clusters 
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2 and 4) resemble those from molecular dynamics of SRJ23-K-RasQ61H (Figure 3.3c 
and ref. (Hocker, Cho et al. 2013)). They are also consistent with those found by 
looking at the high-specificity ligand-receptor pairs in a piecewise fashion (discussed 
above). Thus, irrespective of the specific filter employed, LIBSA provides information 
on the receptor conformations that are best suited to binding small molecules at a given 
pocket.  
 
3.3.3 Optimizing Binding Affinity 
It is important to note that whereas LIBSA can potentially identify a drug core and/or 
receptor conformations that are suitable for ligand binding, it is unlikely to yield high 
affinity hits with desired biochemical properties.  It is therefore important that LIBSA is 
followed up with site-directed VS to optimize potential hits or identify new ones. For 
example, a library of compounds could be generated using programs such as DAIM 
(Kolb and Caflisch 2006) and a pocket can be characterized as preferentially binding a 
molecule with LIBSA. Then other methods such as BOMB (Jorgensen 2009), GANDI 
(Dey and Caflisch 2008), and BROOD (Wang, Evers et al. 2012) can be used to 
generate and optimize additional compounds which can then be screened against only 
the most relevant receptor conformations. Thus the initial library can be built into a 
targeted ligand library that is tailored towards a particular pocket on a particular 
receptor conformation. 
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3.4 Conclusions 
We have presented a computational framework for identifying a consensus-binding site 
on single or ensemble of receptor conformations. The method relies on three simple yet 
novel techniques to remove non-relevant docked poses and calculate binding 
preference. The first tool, affinity filtering, removes low frequency docked poses based 
on the distribution of affinity scores. The second is a high-pass filter that scales down 
protein-ligand contacts based on their probability of occurrence.  The third technique 
combines probing the surface of a target protein by blind docking with the concept of 
signal-to-noise-ratio (SNR) to identify allosteric sites that have the potential to bind 
small molecule ligands. Computation of SNR can be preceded with any of the two 
filtering methods, and can be applied on data generated from blind docking with any 
docking algorithm or other methods that can scan the surface of a target receptor with 
drug-like molecular probes. The resulting protocol, termed LIBSA, provides a metric 
for identifying binding sites and ranking ligands by their consistency of binding to these 
sites. We have demonstrated the usefulness of this approach by applying it on a diverse 
set of known ligands and their receptors, as well as a small set of related ligands docked 
onto a large ensemble of Ras conformers with multiple binding sites. LIBSA was able 
to correctly identify the known active sites as the preferred binding site for the 
respective ligands, and predicted the preference of each of our four test ligands for a 
particular pocket on the Ras structures.  
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Our approach is similar in spirit with an earlier study that has shown that binding 
consistency is a necessary condition for successful docking using multiple runs of a 
genetic algorithm (Cecchini, Kolb et al. 2004). However, the previous study has focused 
on identifying a consistent binding mode at a particular site, whereas the goal of LIBSA 
was to simultaneously identify a binding site and ligands that bind consistently to that 
site. Furthermore, in principle, more rigorous methods such as MD (Durrant and 
McCammon 2011) can be used for binding site identification and scoring. For example, 
Huang et al used microsecond scale explicit solvent MD simulations to show that 
Darunavir binds to HIV protease in a completely different mode than that found in the 
starting crystal structure (Huang and Caflisch 2012). However, while potentially more 
accurate, this approach is too expensive to be used for screening tens of thousands of 
probes against a library of receptor conformers. The computationally much more 
efficient LIBSA can be used alone or in conjunction with MD, depending on need and 
the necessary tradeoff between binding accuracy and computational efficiency. 
Moreover, each of the techniques described in this work can be used either for 
analyzing the binding mode of known drugs retrospectively or for a prospective design 
of new inhibitors. 
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4 Structure Based Drug Discovery with a Fully Flexible Receptor 
4.1 Introduction 
The success of virtual screening currently relies on the ability to accurately rank 
compounds by their predicted affinity (Lyne 2002). This emphasis on docking scores 
inherently overlooks bioactive compounds that have low affinity (Carr and Jhoti 2002). 
Additionally, most screens are carried out using a limited number of receptor 
conformations and do not account for the flexibility of proteins (Lin, Perryman et al. 
2002, Amaro, Baron et al. 2008). By incorporating receptor flexibility into the drug 
discovery process, even transient pockets can be targeted.  
 
The number of drug-like compounds is incredibly vast and is estimated to be on the 
order of 1060 (Bohacek, McMartin et al. 1996). Hence, it is impractical to screen a 
significant fraction of this chemical space against a single site, much less an ensemble. 
Therefore, a fragment based drug discovery (Rees, Congreve et al. 2004, Hajduk and 
Greer 2007) approach has been used to identify probe ligands that bind to allosteric sites 
on Ras using LIBSA. This allows for a limited number of drug cores to be expanded 
into a targeted library developed against a novel pocket with multiple conformations.  
 
To this end, 47 probes were screened against a library of 206 Ras conformations 
sampled from the PDB and MD simulations. The experimentally derived ensemble 
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includes structures from X-ray crystallography and NMR. Probes were first 
characterized as binding a given pocket using LIBSA. Subsequently, they were used to 
identify related compounds from chemical databases, which were then screened against 
only the most relevant receptor conformations. Docking hits were then modified and re-
evaluated using both SNR and affinity as ranking criteria.  
 
Using this approach, the switch regions of Ras were determined to have the most 
potential for binding small molecules. Without the incorporation of an ensemble of 
receptor conformations, several ligand-receptor pairs would have been difficult to 
identify. LIBSA is therefore best suited to assaying binding preference, and identifying 
low affinity probes which can be modified to generate high-affinity ligands.  This 
process ultimately resulted in compounds that show both a high preference and affinity 
for two sites on Ras: the switch 1 effector binding loop and the core β-sheet. In 
summary, LIBSA can be performed on a receptor library that allows for multiple sites 
to be screened simultaneously. Subsequently, by performing a site directed screen, the 
affinity can be minimized at a single site while still retaining preference for the site. 
This allows for multiple ranking criteria to be used in the discovery of hit compounds.  
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4.2 Methods 
4.2.1 Generation of a Ras Ensemble 
To account for that fact that Ras is flexible, several conformations were sampled from 
MD simulations and the PDB. In total, 47 probe-molecules were docked onto 206 Ras 
conformations. To characterize the receptors, we used Cα principal component (PC) 
analysis where the crystal structures served as landmarks for classifying the MD and 
NMR structures. K-means clustering then grouped the conformers into 5 clusters 
defined as: GTP bound state 2 (green), GDP bound (purple), state 1 (orange), 
intermediate between GTP and GDP (red), or intermediate between GTP and state 1 
(blue) (Figure 4.1).  
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Figure 4.1 Overview of the 206 Ras structures used for drug discovery. The PC-space 
projection is accompanied by a word cloud describing how much each cluster is 
populated by MD, X-Ray, or NMR derived data.  The coloring scheme in the word 
cloud represents contribution to cluster size with red being the highest frequency, black 
being the lowest, and green and tan being intermediate.  
 
From the MD simulations, 220,000 receptor conformations were generated over an 
aggregate simulation time of 2.2 µs. Using leader-based RMSD clustering (Seeber, 
Cecchini et al. 2007) on all Cα atoms, 10 conformations were isolated from each of the 
8 systems (Appendix A).  
 
The results from docking on the ensemble were cataloged into a table where each 
ligand-receptor pair was annotated with the following information: pocket SNR, pocket 
 
63 
binding fraction, number of ligand poses after affinity filtering, the preferred pocket 
(see section 4.2.2 – Automatic Determination of Pocket Preference), PC space 
classification for the receptor and various ligand properties (MW, number of rotatable 
bonds, number of heavy atoms, molar refractivity, number of hydrogen bond donors 
and acceptors, total surface area, polar surface area, and non-polar surface area).  
 
4.2.2 Automatic Determination of Pocket Preference  
To address the problem of ligand binding preference across multiple pockets, a decision 
tree was developed to take a set of 4 SNRs and return a single term that describes if a 
ligand binds preferentially to one pocket or to multiple pockets. In the simplest case 
where a ligand binds to a single site, we set a simple threshold value of 60%. For the 
next case, we check if the ligand targets all 4 pockets equally. For this case, if all the 
peaks are within a certain cutoff distance (0.10) of each other then the ligand binds all 
the pockets non-specifically. For the case where binding occurs at 2 or 3 distinct sites, 
but with a multi-modal distribution we found it applicable to denote multiple possible 
binding profiles. A scenario was defined where the probe can target 2 or 3 sites equally, 
and the final possibility is that the ligand hits one site predominantly but still interacts 
with additional pockets.  
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4.3 Results and Discussion 
4.3.1 Isoform and Mutant Specific Differences in Ras 
To explore the possibility that the various Ras isoforms exhibit unique dynamics, we 
performed MD simulations of wild type H-Ras and K-Ras. The switch regions and 
helices 3 & 5 showed distinct dynamics within each isoform (Figure 4.2 insets), and we 
found that K-Ras (purple) samples from a larger conformation space than H-Ras (blue) 
(Figure 4.2A). RMSF calculations also suggested that H- and K-Ras have differing 
dynamics in the catalytic domain (Figure 4.2B).  
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Figure 4.2 Comparison of the dynamics between the H-Ras and K-Ras isoforms.  All 
structures were aligned to core backbone atoms. (A) PC projections for H-Ras (blue) 
and K-Ras (purple) with only the most densely colored regions are shown. (B) RMSF 
calculations of backbone Cα atoms. Insets of the most variable regions of Ras (switch 1, 
switch 2, helices 3 & 5, and loop 7 & 10) are shown.  
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To further support the idea that there are differences in the catalytic domain, we 
compared our MD derived data against data in the PDB. As expected, there are clear 
differences between the GTP bound and GDP bound states of Ras. On average, the 
GDP bound form has a larger distance from either T35 or G60 to Mg2+ as compared to 
the GTP bound form (Table 4.1).  The MD simulations again suggest that the K-Ras 
switch 1 is more dynamic than H-Ras, while the switch 2 regions maintain similar 
distances between Mg2+ and G60.   
 
Table 4.1 Analysis of Mg2+ coordination by T35 on switch 1 and G60 on switch 2.  
Dist. (Å) H-RasGTP* H-RasGDP* K-RasGTP* K-RasGDP* K-RasWT H-RasWT 
T35–Mg2+ 4.5±1.5 5.8±1.4 4.1±0.0 6.8 5.2±2.4 4.2±0.2 
G60–Mg2+ 7.1±0.3 8.1±0.6 7.0±0.1 8.5 8.0±0.5 8.4±0.4 
# Structs. 44 11 2 1 40,000 40,000 
 H-RasG12V K-RasG12V H-RasQ61H K-RasQ61H H-RasQ61L K-RasQ61L 
T35–Mg2+  3.9±0.1 9.4±2.3 4.0 ±0.1 5.4±2.2 8.0 ±4.3 9.9±1.6 
G60–Mg2+  11.1±0.6 9.2±0.4 11.1±0.7 8.4±1.0 11.7±2.1 10.1±1.1 
# Structs. 20,000 20,000 30,000 30,000 20,000 20,000 
Structures marked with an asterisk are from the PDB and all other systems are from MD 
simulations. The distance from Mg2+ to the each residue was calculated using the Cα 
atom and the number of representative structures is listed. 
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Visualization of the PCs for the H-Ras (Figure 4.3A) and K-Ras mutants (Figure 4.3B) 
showed that each system behaves differently. For example, the switch 2 regions of H-
RasG12V and H-RasQ61H have similar switch 1 but distinct switch 2 conformations 
(Figure 4.3C). Additionally, K-RasQ61L and K-RasQ61H have dissimilar switch 1 and 
2 regions (Figure 4.3) and therefore should exhibit distinct binding profiles. The 
different conformational states derived from clustering in PC space primarily take into 
account the motions of switch 1 and 2. Collectively, this suggests that there are 
differences in dynamics between Ras isoforms. 
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Figure 4.3 Overlay of the PC space most frequently sampled by oncogenic K-Ras and 
H-Ras mutants.  The arrows indicate the directions of PC1 and PC2. The space sampled 
by the G12V mutants is colored in gold, the Q61H mutants in green, and the Q61L 
mutants in red. (A) Overlay of the H-Ras mutants in PC space. (B) Overlay of the K-
Ras mutants in PC space.  (C) Overlay of H-RasG12V and H-RasQ61H structures. (D) 
Overlay of K-RasQ61L and K-RasQ61H structures. 
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Due to these differences in dynamics, there should be compounds that display unique 
binding profiles on different Ras conformations, isoforms and mutants. This will allow 
for novel molecules to target specific types of Ras and even particular mutants. By 
preferentially targeting the oncogenic Ras mutants, there will be minimal effect on wild 
type Ras and therefore endogenous signaling. This would ideally result in compounds 
with milder side effects. 
 
4.3.2 Receptor Conformation Correlates with Pocket Accessibility 
To explore the effect of receptor dynamics on ligand binding, we compared the ability 
of the 5 receptor-clusters to bind a set of probe ligands. Low probability docked poses 
were removed using the affinity filter and the SNR was used to assay binding 
preference. The raw number of hits at a particular site was calculated and normalized to 
the receptor cluster size. Without proper normalization, large clusters would simply 
dominate the calculation and low population clusters could be overlooked. We 
determined that GDP bound Ras conformations favor p3a binding more than any other 
conformation (Figure 4.4 B & D), whereas state-1 or state-1 like Ras conformations 
favor p1 binding (Figure 4.4 A & C). A significant conclusion is that the majority of the 
Ras structures determined by X-ray crystallography would overlook binding to p1 and 
that GDP bound Ras conformations are the most amenable to binding ligands at p3a. 
Additionally, there were no ligands that preferentially targeted p2 on a majority of the 
receptors, which was due to the transient nature of the site. This suggests that allosteric 
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sites are able to bind ligands only on certain conformations and that protein flexibility is 
important for the identification of such sites. 
 
Figure 4.4 Overview of how Ras dynamics correlates with ligand binding preference. 
(A & B) Histograms of probe hits at pockets p1 and p3a. (C) Illustration of the binding 
sites p1 and p2 for the state-1 and GDP Ras conformations. (D) Illustration of the 
binding site p3a for the state-1 and GDP Ras conformations.  
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One of the major challenges in drug design and discovery is to find isoform and mutant 
specific ligands. To this end, LIBSA was used to determine if there are any possible 
avenues for identifying isoform/mutant specific binding sites on Ras. The binding of the 
probe compounds to each Ras system is summarized in Table 4.2. The results describe 
ligand binding to the pockets in four frequency levels: none (white), low (yellow), 
medium (blue), and high (green). For each pair of Ras isoforms, pockets with the 
potential for being isoform selective are color-coded (Table A3), where green denotes a 
high potential for being selective, blue denotes a mild potential for being selective and 
black indicates little or no potential for selectivity. 
 
This allows for the most selective binding sites to be readily determined.  Interestingly, 
this revealed that wild type H- and K-Ras show non-specific binding at 38% of the 
pockets i.e. there is no difference in the frequency (colored boxes) with which they bind 
the probes (Table 4.2). For example, in the GTP/State-1* conformation, binding to p3a 
and p3b is identical whereas binding to p1 and p2 is different. Now considering just p1 
on the same conformational state (GTP/State-1*), H-Ras binds the probes with a low 
frequency (yellow) but K-Ras binds the probes with a medium frequency (blue). This 
suggests that despite having a similar global conformation, the local conformation is 
different between the two isoforms. Analogously, on the GTP/GDP* conformation, 
wild type H-Ras did not bind ligands at p1 or p3a but K-Ras bound the ligands at both 
pockets with a medium frequency (blue). This suggests that there are indeed differences 
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in the ability of the isoforms to sample different conformational states and therefore 
bind ligands.  
 
Table 4.2. Comparison of the selectivity between Ras isoforms. 
 H-Ras  K-Ras  
 Pocket GTP/ 
GDP* 
GTP/ 
State1* GTP State1 
GTP/ 
GDP* 
GTP/ 
State1* GTP State1 
w
ild
 
ty
pe
 p1          p2         
p3a         
p3b         
G
12
V
 p1         
p2         
p3a         
p3b         
Q
61
L 
p1         
p2         
p3a         
p3b         
Q
61
H
 p1         
p2         
p3a         
p3b         
The hit frequencies are defined as follows: None is zero hits (white); Low is <25 Hits 
(yellow); Medium is ≥25 and <100 hits (blue); High is ≥100 hits (green). 
Conformational states marked with an asterisk are intermediate between two 
conformational states.  
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Analysis of the G12V mutants showed that 63% of the pockets showed no differences 
in the binding profiles. Likewise, 75% and 56% of the pockets on the Q61L and Q61H 
mutants bind the probes non-specifically, respectively. Overall, this suggests that the 
wild-type Ras isoforms are the best candidates for isoform selective inhibition and that 
distinguishing between oncogenic mutants may be more difficult. For the G12V, Q61L 
and Q61H mutants, the pocket that presented the most potential for discriminating 
between the isoforms was p1. In order to discriminate between oncogenic and wild type 
K-Ras, p3a showed an enhanced ability to bind ligands on the Q61L and Q61H mutants. 
Therefore, the LIBSA analysis suggests that there is a possible avenue for isoform and 
mutant specific inhibition of Ras.  
 
4.3.3 Building a Ligand Database: a Search Space for Ras Inhibitors 
In order to identify novel Ras inhibitors, several chemical databases were downloaded 
to serve as a repository of potential hits in this study. The selected databases were from 
ZINC, NCI, TimTech, Bionet, Chemical Entities of Biological Interest (ChEBI), 
ChemBridge, DrugBank, eMolecules and Maybridge (Table 4.3).  
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Table 4.3 Summary of the ligand libraries used to search for hits using the drug cores. 
Library #Ligands (1000x) 
Bionet 42 
ChEBI 30 
ChemBridge 429 
DrugBank 6.5 
eMolecules 6,225 
Maybridge 52 
NCI 273 
TimTec 914 
ZINC 22,289 
Total 30,261 
 
Currently, there is no single way to search through multiple chemical databases and 
return compounds that meet certain similarity criteria. Accordingly, a small program, 
compiled with the OpenBabel API, was developed to return the Tanimoto score 
between two compounds if it meets a threshold value. OpenBabel was also used to 
return the chemical structures, thus pairing the probe with a similar compound (Figure 
4.5). The database searches and virtual screening were split into two distinct levels. The 
first level was a narrow (high similarity threshold) search while the second level was a 
broader (low similarity threshold) search. The concept behind performing a narrow 
initial search is that not all of the drug cores will give rise to high-affinity docking hits. 
Therefore, this first step eliminates drug cores that do not produce high-affinity hits. 
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Once the probes that produce high-affinity hits have been identified, both the ligands 
and the receptor sets are refined and this decreases the number of screens that must be 
performed. 
 
L1 OpenBabel::OBMol mol1, mol2; 
L2 vector<unsigned int> fp1, fp2; 
L3 OpenBabel::OBFingerprint *pFP1, *pFP2; 
L4 OpenBabel::OBConversion obconversion; 
L5 obconversion.ReadFile ( &mol1, argv[1] ); 
L6 obconversion.ReadFile ( &mol2, argv[2] ); 
L7 pFP1 -> GetFingerprint ( &mol1, fp1 ); 
L8 pFP2 -> GetFingerprint ( &mol2, fp2 ); 
L9 CalculateTanimoto ( fp1, fp2 ); 
Figure 4.5 Code snippet using the OpenBabel API with C++ to compute a Tanimoto 
index between two ligands. The first step in the program is to declare two OpenBabel 
molecule (OBMol) variables. An instance of OBMol holds the connectivity of the 
ligand, atom types, atomic charges etc.  This is followed by declaring a vector of 
unsigned integers, which will serve as the fingerprint for the ligand. The molecules are 
read into the OBMol variables and pointers to fingerprint objects (OBFingerprint) are 
used to compute the fingerprints. Last, the Tanimoto index is computed from the 
fingerprints. 
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Collectively, this approach allows for a single probe to be used to extract molecules 
from open source databases and to then be screened against relevant pocket 
conformations. This fragment-based approach greatly reduces the dimensionality of the 
search space and therefore increases efficiency.  
 
4.3.4 Targeting the Switch 1 Effector-binding Loop of Ras  (p1) 
LIBSA was used to identify probe ligands that preferentially target p1 which were used 
to search through the chemical databases to find molecules with both high preference 
and high affinity. Using the automated tool, we identified 22 ligands as having a 
preference for p1. The 22 probes interacted with 145 receptor conformations; therefore, 
given the large number of ligands and receptors, we restricted the probe search to all the 
databases excluding ZINC. As a first step, a Tanimoto cutoff of 0.90 was used to 
sample a limited number of ligands similar to the probes. From this screen, 9 receptor 
conformers and 6 probes yielded high affinity ligand-receptor pairs (better than -9.0 
kcal/mol). Using this reduced set of probes we searched all 30 million compounds with 
a relaxed Tanimoto index of 0.6 to perform a broader search of chemical space. In total, 
~19,000 ligand-receptor pairs were screened in the process. Two ligands were found to 
have a high affinity for the same MD conformation of K-RasQ61H in a state-1/GTP 
intermediate conformation. 1 was derived from SRJ23 and 2 was derived from CID-
1563977 (Figure 4.6).  
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Figure 4.6 p1 hits identified by LIBSA with their corresponding Vina scores. The probe 
derived from SRJ23 is designated as 1 and the probe derived from CID-1563977 is 
designated as 2. 
  
For each compound we then examined the p1 preference using LIBSA (Figure 4.7). The 
Vina scores for 1 and 2 were -10.9 and -9.4 kcal/mol respectively. Both compounds 
showed a tendency to preferentially bind p1 with SNRs ranging from 1.0 to 1.4 (screens 
performed in triplicate). Interestingly, on run-2 for 2, the reason for the decreased SNR 
was that a noise peak (labeled in red), which was lower in the other two runs, met the 
cutoff value of 40% of the maximum peak height and decreased the SNR (Figure 4.7).  
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Figure 4.7 Affinity spectra (using the AutoDock 4.2 scoring function) for the three 
independent runs of 1 and 2 on K-RasQ61HMD with the SNR for p1 shown in the top 
right of each plot. Shaded red regions represent affinity space sampled after filtering. 
 
Next, 195 derivatives of both compounds were created and re-screened with both 
LIBSA and Vina to determine which modifications resulted in increased SNR or 
affinity. In the top 10 hits from ranking by SNR and affinity, only two compounds 
 
79 
showed up in both ranking methods suggesting that the modifications that confer 
preference and affinity are distinct. Overwhelmingly, 2 produced most of the top 
affinity hits (9 of 10) with scores ranging from -9.6 to -9.9 kcal/mol. 1 produced a 
single result in the top 10 with a value of -9.6 kcal/mol. The max SNR was increased to 
1.31 for 1 and 1.48 for 2. Subsequently, the top ranking derivatives were combined 
using LigMerge (Lindert, Durrant et al. 2012) to generate compounds that should have 
both higher affinity and preference for p1 (Figure 4.8).   
 
L1 high_affinity_list=$(./find_best_affinity.sh | sort –n | head -10) 
L2 high_snr_list=$(grep ligand SNR.dat | sort –nr | head -10) 
L3 for snr in $high_snr_list; do 
L4 for affinity in $high_affinity_list; do 
L5 python ligmerge.py –ligand1 $snr –ligand2 $affinity 
L6 done;done 
Figure 4.8 Overview of the procedure for recombination of the top 10 high-affinity and 
top 10 high-SNR compounds using LigMerge implemented in python with a BASH 
wrapper. The script find_best_affinity.sh returns the AutoDock Vina binding energies 
and prints them to the console. Similarly, the file SNR.dat contains the SNR values for 
the ligand-receptor pairs and all the compounds of interest are named such that they 
contain the keyword ligand. 
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Recombination of the top hits produced 229 compounds (indexed from HJH-0000 to 
HJH-0229). To make sure all the structures were combined properly and no bias was 
introduced, all the ligands were rebuilt from SMILES information with OpenBabel 
(O’Boyle, Banck et al. 2011).   
 
Recombination of the highest affinity ligands with the highest SNR ligands yielded 
compounds that included 1 to 2 modifications. The increases in SNR were modest, and 
the highest value obtained was 1.51. The affinity increases were greatest when both 
drug cores were combined and yielded a best affinity of -10.8 kcal/mol or 12 nM. After 
recombination of the ligands, there is still little overlap in the top 10 compounds when 
ranked by SNR and affinity. This suggests that binding preference should be considered 
something separate from affinity. Importantly, we found that a simple benzene ring and 
naphthalene-containing ring both have a high preference for p1 indicating that a simple 
ring structure, which is common to both compounds, could serve as the minimum drug 
core for p1.  
 
Finally, we generated 72 derivatives of HJH-0229 (best affinity without combining both 
ligands) and found that a compound named 3 had a Vina score of -10.1 kcal/mol 
(original affinity of -9.4 kcal/mol) and an SNR of 1.26 (Figure 4.9). The LogP 
calculated with ChemAxon was 3.8 and the molecular weight was 474 Da. This 
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reflected an increase in affinity of 0.7 kcal/mol and showed an SNR that is consistent 
with the starting compound (2).  
 
Figure 4.9 Chemical structure of 3 and (A) its affinity spectrum with SNR for p1. (B) 
Complex of Ras and 3 (yellow compound) bound at p1, with a single hydrogen bond 
between the compound and I36. The surface of p1 is colored by its electrostatic 
potential and key residues are shown as licorice and colored by atom type. 
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In the end, we chose to modify 2 because it had the stronger SNR for p1 and were able 
to increase its affinity while retaining its preference for p1. The binding of 1 is mediated 
predominantly by van der Waals contacts but forms a key hydrogen bond with the 
backbone amide of I36 using its carbonyl oxygen (Figure 4.9B).  
 
In summary, two compounds (1 and 2) showed a tendency to target a MD derived 
conformation of K-RasQ61H that underwent significant conformational changes 
relative to the starting crystal structure. Most importantly, the side chain of Y40 flipped 
down and opened up a pocket inside switch 1. This allows for the halogenated 
naphthalene ring of 3 to bind in a large pocket on Ras. Additionally, a carbonyl group 
formed a stable hydrogen bond with I36. The compound has a predicted affinity of 39 
nM taken from AutoDock Vina and a high preference for the site as determined by 
LIBSA.  
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4.3.5 Targeting the Core β-sheet of Ras (p2) 
Given the transient nature of probe hits at p2, an ad-hoc approach was used for 
performing a virtual screen against this site. Analysis with LIBSA showed that several 
compounds had a preference (SNR greater than 1.0) for p2, but none showed an 
absolute preference for the pocket. Using these probes, we searched through the 
databases (excluding ZINC) and returned 98 ligands using a Tanimoto cutoff of 0.90.  
 
In total, 37 receptor conformations, 14 of which were X-ray structures and 23 were MD 
structures, were screened against the 98 compounds. After the initial screen, the top 
scoring ligand-receptor pairs were isolated. The molecules that yielded high-affinity hits 
were then used as probes to search through the ZINC database using a Tanimoto cutoff 
of 0.7. Subsequently, we screened an additional 17,000 ligand-receptor pairs. In total, 
~20,000 ligand-receptor pairs were screened during both phases.  
 
After both screening phases, all ligands with an affinity better than -9.0 kcal/mol were 
considered for optimization. The highest affinity ligand-receptor pair produced an 
AutoDock Vina score of -9.7 kcal/mol, which corresponds to an affinity of 76 nM. 
Upon visual inspection, a repeated scaffold was identified that contained only a slight 
modification at two locations. 4 is acetylated at R1 (LogP of 4.0 and molecular weight 
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of 450 Da.) and 5 is methylated at R2 (LogP of 4.0 and molecular weight of 422 Da.) 
(Figure 4.10).  
 
Figure 4.10 Docking hits derived from the probe CID-665904. 4 has an acetyl group at 
R1 and 5 has a methyl group at R2. Overview of the derivatives that produced an SNR 
greater than 1.0 at p2 (6-8) and the ligand that produced the highest affinity (9). 
 
We chose to further investigate the potential of this scaffold to be specific for p2. To 
this end we blind docked 4 (eMolecules-2374361) and 5 (eMolecules-2457656) onto a 
Ras structure determined by X-Ray crystallography (PDB 121P), which is classified as 
a GTP-like structure (see cluster 3 in Chapter 3). The docking was carried out in 
triplicate to compute the relative error associated with each SNR (Figure 4.11).  After 
analyzing ~75 docked poses, the SNRs for the two compounds became statistically 
different with an SNR of 0.95 for 4 and 0.80 for 5.  
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Figure 4.11 Convergence plots of the SNR using the affinity filter. The convergence of 
the SNR for each compound is shown with standard error, which was computed using 
three independent experiments. The insets are the contact spectrum for each compound 
after 256 docking runs. eMolecules-2457656 (red) forms a unique contact with residue 
K5 which is the only unique feature that is sampled by 4.  
 
Therefore, modifications to the phenyl ring on this scaffold could increase the SNR 
and/or affinity for p2. The reason for the difference in SNR was the formation of a 
novel interaction between Lys5 on Ras and the acetyl functional group of 4 (Figure 4.11 
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red-colored inset). To further optimize binding, we generated ~100 additional 
compounds based on visual analysis to see if either affinity or SNR could be enhanced 
further. For all of the additional compounds, LIBSA was used to calculate the SNR 
using blind docking and the affinities at p2 were assayed with AutoDock Vina. To 
determine how affinity was correlated with SNR, we performed a Spearman rank 
correlation analysis and concluded that they are loosely correlated (ρspearman = 0.40).  
 
The compounds that produced a SNR greater than 1.0 had affinities ranging from -8.6 to 
-9.1 kcal/mol (Table 4.4). However, one compound was predicted to have an affinity of 
-10 kcal/mol. The modifications at R1 that produced an SNR greater than 1.0 were a 
carboxylic acid, ethan-1-ol, or 1-butanal. The modification that resulted in the highest 
affinity but only a modest decrease in preference (SNR = 0.90) was a pyrrole ring. 
Therefore, the following compounds may be of relevance to future drug discovery 
efforts against p2 (Figure 4.10).  
 
Upon visual inspection of the docked poses, we found that there is a common binding 
mode for 6, 8, and 9. 7 was the exception, which underwent a conformational change 
around the N-phenylacetamide substructure. Interestingly, this same pose was not 
observed in 8 (Figure 4.12), which has a very similar modification as 7 (Figure 4.10 & 
Figure 4.13B).  
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Figure 4.12 Overlay of the bound conformations of ligands 6-9 at p2 on PDB 121P. 
 
Analysis of the binding site in the presence of 7 and 8 revealed two distinct binding 
orientations in the pocket. For 8, the carbonyl moiety preferentially interacts with K5 
rather than the hydroxyl group interacting with D54 in 7. 
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Figure 4.13 7 and 8 bound at p2 with the surface colored by electrostatic potential and 
key hydrogen bonds shown as green lines. The affinity and SNR are shown besides 
each complex and relevant residues are shown as licorice representations and colored by 
name.  
 
The reason for this conformational rearrangement comes from the replacement of the 
acetyl group with a carboxylic acid group. The hydroxyl group on 7 was the only 
modification that explicitly derived a notable fraction of its binding energy from a 
hydrogen bond (Table 4.4).  
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Table 4.4 Scoring of the Vina poses with the AutoDock 4.1 scoring function to separate 
out the electrostatic (estat), hydrogen bond (hb), van der Waals (vdw), desolvation 
(dsolv), torsional (tors) energy terms (given in kcal/mol). The Vina and AutoDock 
scores are given in kcal/mol and the SNR is also reported. 
Ligand estat hb vdw dsolv tors AutoDock Vina SNR 
6 -0.0 -0.4 -12.0 2.2 2.1 -8.1 -8.6 1.06 
7 -0.0 -1.4 -12.3 2.6 1.8 -9.3 -9.2 1.13 
8 -0.1 -0.2 -12.1 2.5 1.8 -8.1 -9.1 1.04 
9 -0.1 -0.5 -13.1 2.7 1.8 -9.2 -10.0 0.90 
 
For all the compounds, the majority of the binding energy came from van der Waals 
contacts. In fact, the reason for the increased affinity of 9 is the formation of additional 
VDW contacts from the pyrrole ring. Importantly, 6, 8, and 9 all showed the potential to 
form a hydrogen bond with Glutamine 70 with the conserved amine groups, but the 
geometry was unfavorable (Figure 4.13). If the Vina affinity had been the only ranking 
criteria, 9 would have been the best choice; however, ranking by specificity suggests 
that it may have lower preference for p2. To ensure that docking results are not biased 
simply based on affinity, the binding consistency must also be taken into account.  
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In summary, a hydroxyl group (7) holds the most promise for being able to form a 
hydrogen bond with D54 at p2. Residues 5, 39 and 70 are also likely to form hydrogen 
bonds with the compounds and this could interfere with exchange factor binding or 
effector binding (Maurer, Garrenton et al. 2012, Sun, Burke et al. 2012, Shima, 
Yoshikawa et al. 2013). 
 
4.3.6 p3a Directed Screen  
There are 6 compounds that uniquely target p3a on at least 60% or more of the hits 
determined using LIBSA. Due to the low number of hits at p3a, we performed an initial 
similarity search of the probes using a relaxed Tanimoto cutoff of 0.75 using all the 
databases. In total, ~8,000 ligand-receptor combinations were screened. The affinities of 
these compounds yielded significantly lower docking scores (best score of -7.2 
kcal/mol). Therefore, given the relatively low affinity of the isolated compounds, we 
assumed that the compounds derived from these cores would not easily yield high 
affinity docking hits. Therefore, using our current probe library, the results suggest that 
further investigation would be unlikely to yield high affinity docking hits. Furthermore, 
since GDP conformations were determined to best accommodate binding at p3a, 
additional MD simulations and structure determination of GDP bound Ras could yield 
additional conformations more amenable to probe binding at p3a.  
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4.4 Isoform and Mutant Specific Ras Inhibitors 
Given that ~85% of all human tumors are mediated by K-Ras, it is clinically relevant to 
have drugs that discriminate between H-Ras, wild type K-Ras and oncogenic K-Ras. In 
order to discriminate between the H-Ras and K-Ras isoforms, compounds could be 
designed against p1 and the ligands presented in section 4.3.4 could serve as a starting 
point. This is bolstered by our recent study of Andrographolide derivatives and their 
ability to preferentially inhibit K-Ras (discussed in Chapter 5). 
 
To target K-RasQ61L over wild type K-Ras, targeting p3a on a GTP-like or state-1 
conformation holds the most promise (Table 4.2). Similarly, K-RasQ61H also binds 
ligands at p3a on GTP-like conformations and supports the idea that lobe 2 could be 
useful in targeting oncogenic K-Ras. Due to the fact that all the K-Ras systems sample 
from a state-1 or state-1 intermediate conformation; it is unlikely that p1 will be useful 
for targeting oncogenic K-Ras over wild type. The K-RasG12V data gives no potential 
avenue for discriminating against wild type K-Ras. Therefore, p3a holds the most 
promise for oncogenic selective compounds and p1 holds the most promise for isoform 
selective compounds. Considering that p3a binding occurs best on GDP bound Ras, 
such compounds could stabilize oncogenic K-Ras in an inactive GDP-like 
conformation. 
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4.5 Conclusions 
The LIBSA method was used to explore the potential for developing isoform specific 
Ras inhibitors (Chapter 3). By utilizing multiple receptor conformations, it is possible to 
identify novel pockets that are amenable to ligand binding (Lin, Perryman et al. 2002, 
Salsbury Jr 2010). Building on the work of others, we have performed ensemble 
docking in order to identify bioactive compounds that are consistent with a structural 
model (Vasilyeva, Clodfelter et al. 2009). Along this line, other groups have already 
shown the ability of simulations to recreate the correct bound conformation of a ligand 
to its receptor (Buch, Giorgino et al. 2011, Dror, Arlow et al. 2011). This ability to 
correctly determine binding modes is essential for CADD. LIBSA extends the concept 
of site-directed docking on multiple conformations to allow for multiple pockets to be 
screened simultaneously on a flexible receptor such that it seeks to approximate MD 
simulations.  
 
Using LIBSA, the surface of Ras was probed using ~50 different ligand probes and 
slightly more than 200 receptor conformations. This study identified a compound that 
targeted the p1 region of Ras and a series of compounds with a modifiable phenyl ring 
that target p2. Importantly, p1 was most accessible on an MD derived conformation of 
Ras while p2 was most accessible on an X-ray structure. This suggests that p1 is not 
accessible on the crystal structures and that binding would only occur on transient 
conformations. This is supported by a recent study which stabilized a small molecule at 
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p1 using high-pressure NMR (Rosnizeck, Spoerner et al. 2012). Likewise, ligand 
binding at p2 has been demonstrated experimentally in several studies (Maurer, 
Garrenton et al. 2012, Sun, Burke et al. 2012). Hence, there is consistency between the 
LIBSA results and independent studies.  
 
3 binds to a state-1 conformation of p1 and could have multiple biological effects 
including inhibition of effector binding due to stabilization of switch 1 in a weak 
effector-binding conformation. Most notably, D33, D38 and Y40 are reoriented relative 
to state 2. Additionally, it could modulate switch 2 via an allosteric mechanism and 
inhibit exchange factor binding. Along this line, 7 and 8 could also interfere with 
exchange factor binding (Shima, Yoshikawa et al. 2013) since switch 2 contains the 
residues Y64, M67 and Y71 which are critical for binding to the exchange factor Sos 
(Boriack-Sjodin, Margarit et al. 1998). For example, the compound BZI binds to p2 and 
forms a hydrogen bond with D54 on Ras and its derivatives inhibit nucleotide loading. 
Like BZI, 7 also binds to p2 and forms a hydrogen bond with D54. Because LIBSA 
suggests that 7 will bind to an X-ray structure of Ras (PDB 121P), it is likely that such a 
compound would have a similar effect. The analysis of the probe binding to the Ras 
variants suggested that ligands, which bind to p1, could be isoform specific and target 
K-Ras over H-Ras, while ligands that bind to p2 would not be selective. 
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Using the current level of computational power, and a probabilistic view of ligand 
binding (such as LIBSA) it is possible to predict novel ligand-receptor pairs without 
pre-existing crystal structures. Despite the fact that in-silico determination of ligand 
binding is still associated with some level of uncertainty, it does offer promise for 
studying how similar compounds bind to a variety of pockets. In the future, application 
of machine learning (Conway and White 2012) techniques would help better understand 
drug binding.  
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5 Investigation of Andrographolide as an Anti-Ras Agent 
This chapter is based upon, “Hocker, H. J.; Cho, K.-J.; Chen, C.-Y. K.; Rambahal, N.; 
Sagineedu, S. R.; Shaari, K.; Stanslas, J.; Hancock, J. F.; Gorfe, A. A., Andrographolide 
derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function. 
Proc. Natl. Acad. Sci. USA 2013, 110, 10201–10206” and the author retains the right to 
include this article in a dissertation. 
 
5.1 Introduction 
Monomeric Ras proteins are molecular switches that cycle between inactive GDP-
bound and active GTP-bound conformational states and regulate multiple cell signaling 
pathways that include the MAPK cascade (Malumbres and Barbacid 2009). Activation 
of Ras is facilitated by guanine nucleotide exchange factors (GEFs) and inactivation by 
GTPase activating proteins (GAPs) (McCormick and Wittinghofer 1996, Scheffzek 
1997).  About 15% of all human cancers are associated with somatic Ras mutations at 
amino acid positions 12, 13, or 61 that impair GAP-catalyzed GTP hydrolysis.  Of the 
three most common human Ras isoforms N-, H- and K-Ras4B, mutations on K-Ras4B 
(hereafter K-Ras) are most prevalent in cancers, including in up to 90% of cases in 
pancreatic cancer (Prior, Lewis et al. 2012). However, decades of efforts to inhibit 
oncogenic Ras by small molecules have to date been unsuccessful (Wang, Fang et al. 
2012). Attempts to abrogate the plasma membrane binding of Ras, which is required for 
biological activity, by inhibiting farnesyl transferase (DeGraw, Keiser et al. 2010, 
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Niessner, Beck et al. 2010) have failed because N-Ras and K-Ras are also good 
substrates for geranyl-geranyl transferase 1 in cells treated with farnesyl transferase 
inhibitors (Rowell, Kowalczyk et al. 1997, Whyte, Kirschmeier et al. 1997). Other 
efforts along this line include the development of farnesyl analogues, currently in 
clinical trial (Kloog, Blum et al. 2008), and other compounds that dislodge Ras from the 
plasma membrane (Cho, Park et al. 2012, van der Hoeven, Cho et al. 2012). Although 
the potential therapeutic value and mechanism of action of these compounds are still 
under investigation, it is clear that they do not directly bind to Ras. Recent efforts by us 
(Grant, Lukman et al. 2011)  and others (Buhrman, O′Connor et al. 2011, Maurer, 
Garrenton et al. 2012, Sun, Burke et al. 2012) toward direct inhibition of Ras have 
yielded promising initial results. For instance, using fragment screening, 
crystallography and other methods, two groups reported ligands that directly bind Ras 
and inhibit GEF-dependent nucleotide exchange (Maurer, Garrenton et al. 2012, Sun, 
Burke et al. 2012). However, it is unclear if, or how, these ligands could lead to drugs 
that act against constitutively active, GTP-loaded mutant Ras.  
 
GTP-Ras can exist in at least two conformational states (Spoerner, Wittinghofer et al. 
2004, Araki, Shima et al. 2011). When in state 1 Ras has reduced affinity for effectors 
and harbors open pockets (Spoerner, Herrmann et al. 2001, Muraoka, Shima et al. 2012) 
whereas state 2 Ras is able to effectively bind effectors (Liao, Shima et al. 2008, Shima, 
Ijiri et al. 2010). In principle small molecule inhibitors that can selectively target the 
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state 1 conformation can have the potential to inhibit Ras signaling by interfering with 
either effector or exchange factor binding. Along this line, a recent study found a 
compound that binds to an open switch 1 conformation of state 1 Ras (Rosnizeck, 
Spoerner et al. 2012). In this work we use ensembles of K-Ras obtained from molecular 
dynamics (MD) simulations that sample state 1 and other intermediate structures 
(Prakash, Sayyed-Ahmad et al. 2012) to address two major questions. First, evaluate if 
the reported anti-cancer activity (Jada, Matthews et al. 2008) of andrographolide (AGP), 
a diterpene from the medicinal plant Andrographis paniculata (Behrens, Brockhoff et 
al. 2009), and its benzylidiene derivatives involves direct inhibition of Ras; and second, 
to use these compounds to test a unique hypothesis that prolonged inhibition of 
nucleotide exchange can abrogate the function of oncogenic mutant Ras. Combining 
data from ensemble docking, simulations and experiments in intact cells, we show that 
AGP and its derivatives inhibit Ras function by preventing GEF-induced nucleotide 
exchange. We further show that prolonged treatment with AGP derivatives significantly 
impairs oncogenic K-RasG12V signaling and highlight how inhibiting nucleotide 
exchange can be a valid approach to abrogate the function of oncogenic mutant Ras. 
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5.2 Materials and Methods 
5.2.1 Ensemble Docking 
Expanding the concept of a relaxed complex scheme for structure-based drug discovery 
(Lin, Perryman et al. 2002, Amaro, Baron et al. 2008), we built an ensemble of K-Ras 
conformers that contained infrequently sampled structures. Such structures could 
potentially harbor open binding sites that are invisible in crystal structures. To this end, 
we isolated an ensemble of 75 structures based on RMSD clustering of GTP-bound K-
RasQ61H conformers derived from previously reported MD simulations (Prakash, 
Sayyed-Ahmad et al. 2012). Taking advantage of the small number of related 
compounds that we were interested in we deliberately used a small RMSD cutoff of 1.3 
Å to generate a large number of clusters, and used all of the cluster centroids in order to 
include infrequently visited K-Ras conformers. Blind docking against these structures 
was carried out using AutoDock 4.2 (Morris, Goodsell et al. 1998) and a search area 
that encompasses the entire Ras structure plus a buffer space of 10 Å in each direction. 
GTP was retained to exclude non-specific hits at the catalytic site (see Appendix B for 
detail and controls). 
 
5.2.2  Binding Site Identification and Selection of Ligand Poses 
In order to account for the joint probability that K-Ras samples a given conformation 
and AutoDock consistently places the ligand to a consensus site, binding sites were 
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identified based on the size of both the ligand and receptor clusters. Therefore, ligand-
receptor pairs were ranked by the product of the fraction of Ras conformers within a 
cluster and the fraction of ligand poses within a ligand cluster (see Table 2). Visual 
inspection of the high-ranked complexes and histograms of contact frequencies were 
then used to identify most commonly targeted pockets (see Appendix B).  
 
5.2.3 Molecular Dynamics Simulations 
After docking and site identification we tested if binding at the predicted sites is viable 
by performing MD on selected protein-ligand complexes. The simulation details were 
similar to those described previously (Prakash, Sayyed-Ahmad et al. 2012) and in 
Appendix B. By assigning different initial velocities we generated two sets of five 
separate trajectories with SRJ23 bound to K-Ras at either of two preferred sites (p1 and 
p2).  
 
5.2.4 In Vitro Cell-based Assays 
Based on initial work that formed the basis of this study (Jada, Hamzah et al. 2006, 
Jada, Matthews et al. 2008) AGP, SRJ09 and SRJ23 were prepared as reported before 
(Jada, Hamzah et al. 2006) (see Appendix B text for proof of purity). Antibodies against 
H-Ras (F235) (no. sc-29) and N-Ras (F155) (no. sc-31) were obtained from Santa Cruz 
Biotechnology (CA). Monoclonal K-Ras antibody (R3400) was obtained from Sigma-
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Aldrich. Rabbit phospho-p44/42 mitogen-activated protein kinase (MAPK) (ERK1/2) 
(Thr202/Tyr204) antibody (no. 9101), mouse anti-phospho-EGF receptor (Y1068) 
antibody (no. 2236) and rabbit total EGF receptor antibody (no. 2232) were purchased 
from Cell Signaling Technology. Monoclonal anti-Ras antibody (no. 610001) was 
obtained from BD Transduction Laboratories. For cell culture, baby hamster kidney 
(BHK) cells were maintained in Dulbecco’s modified Eagle medium (DMEM) (Gibco) 
supplemented with 10% donor calf serum (DCS) and 2 mM L-glutamine. Ras-GTP 
levels were measured in a glutathione S-transferase (GST)-Ras binding domain (RBD) 
pull-down assay as described previously (Roy, Luetterforst et al. 1999). Samples were 
analyzed by quantitative Western immunoblotting using pan-Ras or Ras isoform-
specific antibodies.  
 
The potential of AGP, SRJ09 and SRJ23 to induce growth inhibition against PC-3 
(prostate), HCT-116 (colon) and MDA-231 (breast) cells was assessed according to 
Jada et al (Jada, Matthews et al. 2008). Briefly, exponentially growing cells were 
seeded in flat-bottom 96-well plates at a density of 2000 cells/0.18 mL per well and 
incubated overnight for cell attachment. The cells were then treated with compounds at 
a final concentration range of 0.1 to 100 µM (n = 4). The control wells were introduced 
with 0.1% of DMSO equivalent to the highest amount of DMSO used as a vehicle in the 
compound-treated wells. After 96 h of incubation in a CO2 incubator, the cell viability 
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was determined by MTT assay. The 50% growth inhibition values (GI50) were obtained 
from the dose-response growth inhibitory curves. 
5.3 Results and Discussion 
5.3.1 AGP and Benzylidene Derivatives Target the Switch Regions of K-Ras 
AGP has oxidative, anti-viral and anti-cancer properties and its benzylidene derivatives 
(Figure 5.1) exhibit an enhanced ability to induce apoptosis and G1 cell cycle arrest in 
breast and colon cancer cells (Jada, Matthews et al. 2008, Hung, Hung et al. 2010).  
 
Figure 5.1 Chemical structures of AGP and its benzylidene derivatives SRJ09, SRJ10,  
and SRJ23. 
 
Other studies have shown that AGP interferes with MAPK activation, increases 
sensitivity of Ras transformed cells to radiation treatment in-vitro and in-vivo (Carretta, 
Alarcon et al. 2009, Hung, Hung et al. 2010, Levita, Nawawi et al. 2010, Lim, Chan et 
al. 2012), and is not toxic (He, Li et al. 2003). The drug-like (Lipinski 2000)  AGP has 
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3 hydrogen bond donors and 5 acceptors, and a LogP of 2.6. Its slightly larger SRJ 
series of derivatives each have 1 donor, 5 acceptors and an estimated LogP of 5.6.  
 
We docked these ligands onto a diverse set of 75 K-Ras conformers and ranked them by 
their preference for a given site and receptor conformation as described in Methods (see 
5.2) and Appendix B, with appropriate controls (Figure B1). We found that the ligands 
preferentially target three distinct pockets: p1, p2, p3. The residues defining these 
pockets are listed in Table 5.1 and their location on the 3D structure is shown in Figure 
5.2.  
 
 
Table 5.1 Pockets on K-RasQ61H targeted by AGP and derivatives SRJ09, SRJ10 and 
SRJ23.  
Pocket Residues Locations 
1 17, 20, 21, 24, 25, 29, 30-40, 55 and 57 α1, switch 1, β2 
2 4-7, 35-39, 54-59, 61-78 β1, β2, switch 2 
3 97, 101, 107-111, 137-140, 162, 163 166 α5, β5, β6, loops α3/β5 and α4/β6 
 
 
103 
 
Figure 5.2 Overview of the K-RasQ61H structures derived from MD simulations for 
ensemble docking. From among the 75 unique K-Ras conformers used for docking 
(Materials and Methods), 5 representative cluster centroids are shown along with the 
percentage of the total conformers they represent. Pockets most frequently targeted by 
SRJ23 are highlighted in red van der Waals spheres. Notice the major conformational 
changes in switch 1 (cyan) and switch 2 (green). 
 
Pocket p1 comprises the effector binding loop (residues 30-40), β2 (residues 55 and 57) 
and several residues on α-helix 1. Pocket p2 involves the core β-strands 1 and 2, part of 
the effector loop and switch 2. The C-terminal pocket p3 is bounded by α-helix 5 plus 
the N-terminal and preceding loop residues of β5 and β6. Remarkably, each of these 
pockets is very similar to those we have previously characterized using a different 
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approach and a different set of probes (Grant, Lukman et al. 2011). Mapping the 
energetic preference of small molecule fragments by FTMap (Brenke, Kozakov et al. 
2009) identified the same binding hotspots, with binding preference for each site being 
modulated by protein motion (Figure B2). Opening of pocket p1 is primarily a function 
of the displacement of Y40 that occurs during the simulations (Figure B3 and Figure 
B4). Relative to the reference X-ray structure Protein Data Bank (PDB) ID code 3GFT 
the Cα of Y40 is displaced by 4 Å and the side chain oriented away from D38 (Figure 
B3). Similarly, expansion of a narrow surface groove between switches 1 and 2 (Figure 
B4B, D) opens p2, a pocket surrounded by hydrophobic (I36 and M67) and polar 
residues (Y64 and E37) with V7 at the bottom (Figure 5.3B). 
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Figure 5.3 Overview of transiently opening pockets 1 and 2 on K-RasQ61H with 
relevant residues colored according to their electrostatic potential. (A) Docking pose of 
SRJ23 at pocket 1, where its phenyl group occupies the space previously occupied by 
Y40 and is stabilized by the residues I21 and T20. (B) Docking pose of SRJ23 at pocket 
2 opened by the movement of Y71 and lined by hydrophobic residues I36 and M67. (C) 
MD-optimized complex of SRJ23 at pocket 1. (D) The conformation in C is modified to 
visualize the proximity of SRJ23 to Mg
2+ and GTP (switch 1 is now shown as a 
transparent surface). The hydroxyl group on the lactone ring of SRJ23 forms a hydrogen 
bond with the α-phosphate of GTP as well as an electrostatic contact with Mg
2+ similar 
to that made by the hydroxyl of T35 on Ras (Spoerner, Herrmann et al. 2001). 
Electrostatic potentials were calculated using the Adaptive Poisson-Boltzmann Solver 
(Baker, Sept et al. 2001) 
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To check if structures within each cluster have reasonably similar binding site 
topologies we calculated the standard deviation of the mean solvent accessible surface 
area of p1 residues, which was found to be 33% smaller for structures within clusters 
(averaged over all 75 clusters) than the corresponding value across clusters. 
 
Whereas the parent compound AGP displays some preference for p3 in addition to p1 
and p2, the derivatives have much less preference for p3, as can be seen from the 
binding frequency histograms in Figure B5 for the top 5 ligand clusters. In fact the SRJ 
ligands hit p3 only when docked onto the crystal structure. When the structure is 
relaxed but still somewhat close to the starting crystal structure PDB ID code 3GFT (Cα 
RMSD of 2.8 and 2.9Å respectively for switches 1 and 2) the top ranked ligand cluster 
targets p2 with a probability of 5.6%. When it adopts a more open switch conformation 
(3.6 and 4.3Å), SRJ23 (3,19-(3-chloro-4-fluorobenzylidene) andrographolide) targets 
p1 with a probability of 3.1% (Table 5.2).  
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Table 5.2 Ranking ligand–receptor pairs by the joint probability of occurrence of a 
given receptor conformation and ligand pose, followed by visual pocket identification. 
Receptor Ligand Receptor-ligand pair  
Cluster Fraction total conformers Cluster 
Fraction total 
poses Ranking by joint probability, % Pocket ID 
4 0.09 2 0.66 5.6 2 
2 0.11 3 0.27 3.1 1 
7 0.04 1 0.64 2.9 3 
1 0.12 17 0.20 2.4 2 
1 0.12 18 0.17 1.4 2 
 
 
To probe whether the ligand might prefer a region proximal to p2, such as the site 
occupied by ligands BZIM and its halogenated derivative DCAI (Maurer, Garrenton et 
al. 2012), we docked SRJ23 onto the K-Ras-BZIM structure (PDB ID code 4DSU). We 
found that SRJ23 does not recognize this region since four of the top five ligand-
clusters (predicted affinity 0.04-1.2µM) targeted p3. We conclude that pockets near the 
highly dynamic canonical switches, which became accessible during the simulations, 
represent the most probable binding sites for AGP and its derivatives.  
 
5.3.2 MD Simulations of K-Ras/SRJ23 Complexes Suggest Stable Binding at p1 
but Not p2 
 To further evaluate the viability of ligand binding at p1 or p2, we conducted multiple 
MD simulations of K-Ras in complex with SRJ23 with different initial velocity 
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assignments. The ligand dissociated within 60ns in 4 out of 5 of the runs with SRJ23 at 
p2 and after an additional 40 ns in the 5th run (Figure B6A). By contrast, the K-
Ras/SRJ23 complex remained stable (with 45-80% of its surface area buried) during 4 
out of 5 simulations with SRJ23 bound at p1 (Figure B6A, C). In the remaining run 
switch 1 moved away from the GTP and the pose of SRJ23 was altered, but it did not 
dissociate. These results suggest that p1 is the preferred pocket for our ligands despite 
the fact that p2 showed up repeatedly during docking (Figure B6). We conclude that 
switch 1 is a viable target whose dynamics leads to the opening of a pocket that can 
accommodate even comparatively large ligands such as SRJ23.   
 
During the simulations with p1-bound SRJ23, the ligand forms a hydrogen bond with 
the α-phosphate of GTP (Figure 5.3D), but it targets the same pocket when docked onto 
a nucleotide free-like conformer (Figure 5.4B).  
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Figure 5.4 Comparison of known Ras structures bound to SOS and small-molecule 
ligands. (A) Overlay of the switch 2 region of a K-Ras–SRJ23 snapshot (orange), the 
crystal structure of K-RasG12D–DCAI from PDB ID code 4DST (purple, with only 
residues 62–75 shown for clarity), K-Ras–0QX from PDB ID code 4EVP (yellow, 
residues 62–75), and two structures of H-Ras–SOS from PDB ID codes 1NVV 
(ice blue) and 1BKD (cyan). (B) Projection of simulated K-Ras conformers onto a PC 
space defined by crystallographic structures, with the cluster of GDP–H-Ras structures 
highlighted in blue and the cluster of loss- of-function mutants in orange. PDB ID code 
4DST (purple) lies in the major GTP cluster, whereas PDB ID code 4EPV (yellow) is 
intermediate to the GTP and GDP clusters. Two K-Ras–ligand conformations 
from docking (MD-Lf, green dots) are shown to illustrate the ability of MD to capture 
putative excited-state structures with open p1 that are preferred by our ligands. An 
example of simulated K-Ras–SRJ23 (MD- Lb) lies between Ras–SOS (cyan/ice blue) 
and Ras– inhibitor (purple/yellow) conformations. The crystal structure of nucleotide-
free H-Ras (PDB ID code 1BKD) is also shown, with SRJ23 docked at switch 1. SRJ23 
is shown as a yellow surface and switches 1 and 2 as blue and green surfaces, 
respectively. The Bio3D package (http://thegrantlab.org/bio3d) was used to generate the 
figure in B. 
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This indicates that the nucleotide is not required by SRJ23 for binding but it might 
stabilize the bound ligand. As noted earlier, SRJ ligands target an open switch 1 
conformation in which, for instance, the distance between D33 and D38 Cα atoms is 15 
Å instead of 11 Å as in the classic (i.e., closed) GTP bound structures (Figure B3). 
Relaxing the K-Ras-SRJ23 complex by MD further expanded the pocket to better 
accommodate the halogenated phenyl ring (Figure 5.3A, C). This led us to the question 
of what might constitute a minimal scaffold to target this pocket. To address this 
question, we fragmented SRJ23 into 16 substructures and docked them onto the K-Ras 
conformer that served as the starting point for the K-Ras-SRJ23 simulations. A 
fragment common to all three SRJ ligands has the highest preference for this site 
(256/256 poses) (Figure B7A). We predict that this three-membered ring represents the 
chemical signature of AGP derivatives to target p1 but the role of the halogenations for 
affinity, if any, is not obvious (see Appendix B). To test if compounds that share 
structural similarity with SRJ bind to p1 we carried out virtual screening of about 1000 
ligands from the ZINC database selected based on a Tanimoto similarity index of 0.6 
(see Appendix B). The results suggest that these ligands would bind to p1 with a micro- 
to nano-molar affinity (AutoDock Vina energy score of -6 to -10 kcal/mol) when switch 
1 is open (Figure B7B). Their affinity for closed switch 1 conformations was about 
three orders of magnitude weaker. This result not only reemphasizes the correlation 
between Ras dynamics and ligand binding but also suggests that it may be possible to 
find other small molecule Ras binders that preserve the key features of SRJ but bind 
with better affinity (see Figure B7C).  
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5.3.3 Stabilization of a Unique K-Ras Conformation 
The docking results indicate that our ligands favor state 1-like conformers with open 
switch 1 (Figure 5.4B). To test if the ligands stabilize a particular Ras conformation, we 
used a principal component (PC)-based analysis developed previously (Gorfe, Grant et 
al. 2008, Grant, Gorfe et al. 2009, Lukman, Grant et al. 2010, Grant, Lukman et al. 
2011) to map conformers from K-Ras-SRJ23 trajectories onto a PC plane defined by 
crystal structures. Figure 5.4B shows that p1-bound SRJ23 stabilizes conformations that 
are different from the canonical GTP/GDP or nucleotide-free states (see Figure B8 for 
the full PC data). Alignment of the simulated K-Ras structures with p1-bound SRJ23 
onto those from a control ligand-free simulation further shows stabilization of D38 in an 
orientation that allows for an opening of a pore behind switch 1 (Figure B3). Given their 
structural similarity, we expect SRJ09 and SRJ10 will have a similar effect.   
 
5.3.4 Proposed Mechanism of Action 
Recent reports revealed that ligand binding at a pocket between the core β-sheet and 
helix 2 of K-Ras stabilizes alternate side chain conformations at or around switch 2 and 
thereby affects exchange factor binding (Maurer, Garrenton et al. 2012, Sun, Burke et 
al. 2012). For instance, the side chains of both Y64 and Y71 were displaced in these 
ligand-bound structures relative to a SOS-bound H-Ras structure (Maurer, Garrenton et 
al. 2012, Sun, Burke et al. 2012). We therefore compared the orientation of these side 
chains in our K-Ras-SRJ23 conformers with those in K-Ras-DCAI (PDB ID code 
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4DST), H-Ras/SOS (PDB ID codes 1BKD and 1NVV (Boriack-Sjodin, Margarit et al. 
1998, Margarit, Sondermann et al. 2003)) and other K-Ras/ligand complexes (PDB ID 
code 4EPV) (Figure 5.4A). The orientation of Y71 in K-Ras/SRJ23 mimics that in K-
Ras-DCAI and 4EPV. Moreover, Y64 is displaced by >5 Å (Cα atom) in K-Ras-SRJ23 
relative to its position in the H-Ras/SOS complex. Although other modes of action 
cannot be ruled out, these observations suggest that our ligands may stabilize Ras in a 
conformation that is not conducive for GEF binding. AGP and its derivatives could thus 
inhibit GEF-induced nucleotide exchange in a similar manner as those reported by 
Maurer et al and Sun et al (Maurer, Garrenton et al. 2012, Sun, Burke et al. 2012).  
 
5.3.5 In Vitro Assays Indicate that SRJ Compounds Inhibit Ras GTP-loading 
and Cancer Cell Growth 
To explore the effects of AGP and its derivatives on Ras function in intact cells we first 
measured activation of the Ras/MAPK cascade in response to EGF stimulation. Serum 
starved BHK cells were incubated with AGP or derivatives for 6 h and stimulated with 
EGF. Figure 5.5A shows that SRJ09 and SRJ23 significantly reduced Ras GTP-loading, 
as measured in RBD pull-down assays. The reduction in Ras activation correlated 
closely with a concomitant reduction in MAPK activation (Figure 5.5B). The 
concentrations of AGP required to inhibit EGF stimulated ERK activation were ~10fold 
higher than the active concentrations of SRJ09 and SRJ23, indicating that the SRJ 
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compounds were considerably more potent than the parent compound (Figure 5.5B 
compared to Figure B9B).  
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Figure 5.5 Mean fold increase in Ras-GTP (A) and ppERK (B) ± SEM from three 
independent experiments where wild-type BHK cells were treated with SRJ09 or SRJ23 
for 6 h in the absence of serum, followed by 25 ng/mL EGF stimulation for 2 min. Ras-
GTP levels were measured using an RBD pull-down assay, and ppERK levels were 
measured by quantitative immunoblotting. (C) Representative blots from three 
independent experiments in which wild- type BHK cells were treated with 5 µM SRJ23 
for 6 h in the absence of serum, followed by 25 ng/mL EGF stimulation for 2 min. 
Levels of K-, H-, and N-Ras– GTP loadings were measured using an RBD pull-down 
assay, and phospho- EGF receptor (EGFR; Y1068) levels were measured by 
quantitative immu- noblotting. (D) Mean ± SEM from three independent experiments in 
which BHK cells stably expressing oncogenic Ras isoforms were treated with 5 µM 
SRJ09 or SRJ23 for 6 h in the absence of growth serum. ppERK levels were measured 
by quantitative immunoblotting. Mean Ras-GTP (E) and ppERK (F) ± SEM from three 
independent experiments in which BHK cells stably expressing oncogenic K-Ras were 
treated with 5 µM SRJ09 or SRJ23 for 72 h. Growth media with the drug were replaced 
every 24 h. Ras-GTP levels were measured using an RBD pull-down assay, and ppERK 
levels were measured by quantitative immunoblotting. Differences between DMSO- 
and drug- treated cells were assessed using one-way ANOVA tests. Significant differ- 
ences are indicated (*P < 0.05; **P < 0.01; ***P < 0.001). 
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We then immunoblotted the RBD pull-downs with isoform specific antisera to 
determine if all Ras isoforms were equally sensitive to SRJ09 and SRJ23.  Figure 5.5C 
shows that K-Ras GTP-loading was significantly suppressed by SRJ09 and SRJ23 
whereas H-Ras and N-Ras GTP-loading were much less sensitive. For example, SRJ23 
reduced K-Ras, H-Ras and N-Ras GTP levels by 47%, 28% and 13% respectively. The 
structural basis for K-Ras selectivity is not immediately clear but it is consistent with 
previous suggestions (Gorfe, Grant et al. 2008, Lukman, Grant et al. 2010) that K-Ras 
might be more dynamic than H-Ras and samples open switch 1 conformations more 
frequently. This is supported by results from new MD simulations of wild type K- and 
H-Ras (Figure B10). Importantly none of the compounds suppressed activation of the 
EGFR as measured by Y1068 phosphorylation. Furthermore, 5 µM SRJ09 does not 
inhibit CRaf-mediated MAPK activation (Figure B11), showing that the 
Andrographolides do not inhibit any of the kinases in the Raf/MEK/ERK signaling 
cascade. These results strongly suggest that AGP, SRJ09 and SRJ23 directly target Ras 
to block the exchange of GDP for GTP and thus prevent Ras activation. Consistent with 
this mechanism of action a 6 h incubation in SRJ09 and SRJ23 (5 µM) had no 
measurable effect on the extent of GTP-loading of oncogenic mutant K-, H- and N-
RasG12V, or on the extent of MAPK activation in Ras transformed cell lines (Figure 
5.5D).  Oncogenic mutant Ras is constitutively GTP-loaded because the oncogenic 
mutation blocks the ability of GAP to stimulate GTP hydrolysis and return Ras to the 
inactive GDP-bound ground state.  
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We reasoned however that the intrinsic GTPase activity of oncogenic mutant Ras must 
eventually return Ras to the ground state even though the expected rate would be very 
slow (~8-17 h, with Kcat of 1-2x10-3 min-1) (Krengel, Schlichting et al. 1990, Polakis 
and McCormick 1993).  Once in the GDP-ground state oncogenic Ras would then need 
to interact with an exchange factor to be reloaded with GTP. If the SRJ compounds are 
present at this point and bind to RasG12V-GDP (or other conformational sub-states 
with an open switch 1 conformation), GTP loading may be abrogated. We tested this 
hypothesis by incubating oncogenic mutant K-Ras transformed cells in SRJ09 and 
SRJ23 (5 µM) for 3 days to give sufficient time for GTP hydrolysis and thus reveal a 
requirement for GDP-GTP exchange. Remarkably, after this prolonged incubation 
period SRJ09 and SRJ23 reduced K-RasG12V GTP levels by ~50% (Figure 5.5E), 
which resulted in a concomitant reduction in ppERK levels in K-RasG12V transformed 
cells (Figure 5.5F).  Moreover, the ability of AGP, SRJ09 and SRJ23 to induce growth 
inhibition against PC-3 (prostate), HCT-116 (colon) and MDA-231 (breast) cancer cells 
was assessed as described previously (Jada, Matthews et al. 2008). PC-3 cancer cells 
harbor wild type Ras for all the 3 different isoforms (H-, K- and N-Ras) whereas HCT-
116 and MDA-231 cancer cells express G13D mutant K-Ras and wild H- and N-Ras. 
Table 5.3 shows the GI50 values of AGP, SRJ09 and SRJ23 in this panel of cancer cell 
lines. 
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Table 5.3 Growth-inhibitory effect of AGP, SRJ09, and SRJ23 on prostate (PC-3), 
colon (HCT-116), and breast MDA-231 cancer cells. 
 GI50, µM 
Compounds PC-3* HCT-116† MDA-231† 
AGP 9.7±1.3 4.5±1.8 5.9±1.4 
SRJ09 12.4±1.3 3.1±0.7 5.0±0.4 
SRJ23 6.6±1.3 4.0±1.2 5.8±0.7 
Ras status was obtained from the Catalog of Somatic Mutations in Cancer, Wellcome 
Trust Sanger Institute. Values represent mean ± SD of three in- dependent 
experiments. *Wild-type for H-, K-, and N-Ras. 
†Mutant K-Ras (substitution, p.G13D) and wild-type for H- and N-Ras. 
 
One can see that SRJ09 and SRS23 are generally more active than the parent compound 
AGP and, more importantly, cancer cells with endogenous mutant K-Ras (HCT-116 and 
MDA-231) were found to be significantly more sensitive towards the compounds. The 
mean GI50 value in these cells was approximately half compared with the cancer cell 
harboring wild type K-Ras (PC-3). We conclude that cancer cells with mutant Ras are 
more sensitive towards the compounds, which is consistent with our results with 
ectopically expressed mutant Ras. 
 
Taking together the computational and cell biology results we conclude that SRJ09 and 
SRJ23 bind to GDP-bound Ras and prevent GTP loading thus effectively blocking 
GDP-GTP exchange in live cells. Using these compounds which directly target Ras we 
also show for the first time that exchange factors are required to maintain oncogenic 
 
120 
mutant Ras in the active GTP-bound state, and that inhibiting nucleotide exchange is a 
valid approach to abrogate the function of oncogenic mutant Ras.  
 
5.4 Conclusion 
Using molecular docking and simulations, we show that AGP and its derivatives bind to 
the switch regions of Ras, preferentially targeting a transient pore behind switch 1 as 
well as a groove between switches 1 and 2. Binding of AGP derivatives to p1 stabilizes 
Ras in a unique conformation where key residues on the nucleotide binding switches, 
such as Y64 and Y71, reorganize in a manner that would impair interaction with Ras 
modulators. Combining these findings with earlier reports (Maurer, Garrenton et al. 
2012, Sun, Burke et al. 2012), we predict that AGP derivatives should inhibit Ras 
function by preventing GEF-assisted nucleotide exchange. We confirmed this prediction 
by experiments showing that SRJ treatment blocks acute GTP-loading of wild type Ras. 
Even more intriguing was the observation that extended incubation with SRJ 
compounds also reduced oncogenic mutant Ras-GTP levels and hence signal output. 
The likely explanation for this observation is that the SRJ ligands deplete the pool of 
GTP-Ras over time by allowing intrinsic hydrolysis of bound GTP whilst preventing 
reactivation via GEF-catalyzed GDP-GTP exchange. This mechanism can operate 
because oncogenic mutations prevent the ability of GAP to accelerate the intrinsic 
GTPase activity of Ras and only modestly reduce the actual intrinsic GTPase activity 
(Neal, Eccleston et al. 1988, Gideon, John et al. 1992, Chung, Benson et al. 1993, 
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Eccleston, Moore et al. 1993). In showing that GEF mediated nucleotide exchange is 
critical for oncogenic Ras signaling our findings represent an important proof of 
concept for anti-Ras drug discovery. Drug development need not be limited to ligands 
that abrogate effector interactions of GTP-loaded Ras, or directly inhibit Ras effectors 
but may be expanded to exploit the requirement of GEF-mediated GTP loading for a 
sustained signaling through oncogenic Ras. We therefore propose that future efforts 
toward Ras inhibition should additionally consider ligands that abrogate GEF binding 
and, or prevent GDP/GTP exchange; such ligands may potentially be more effective 
and selective given the fewer number of exchange factors than effectors and the 
possibility that Ras isoforms may differ in dynamics and response. 
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6 Discussion  
Cancer is the second leading cause of death in the US and there are about 13.7 million 
Americans having a history of cancer development. Moreover, another 1.6 million were 
diagnosed in 2013 (ACS 2013). Due to the high number of people with the disease, and 
its ability to evolve over time, new drugs are needed to meet this ongoing clinical 
demand (Hamburg and Collins 2010, Chin, Andersen et al. 2011). Along this line, as 
personalized medicine becomes part of standardized clinical care, an increased number 
of drugs will be needed to treat people in such a tailored manner (Ginsburg and 
McCarthy 2001, Jain 2006).  
 
Ras is one of the most prolific oncogenes ever discovered; yet there are no drugs on the 
market designed to specifically treat people with oncogenic Ras (Wang, Fang et al. 
2012).  Due to this fact, there is a pressing need for novel drugs that have the ability to 
interact directly with and inhibit oncogenic Ras. Until recently, there was little evidence 
or indication that allosteric sites even existed on Ras (Spoerner, Graf et al. 2005, Zhu, 
Baek et al. 2006, Grant, Lukman et al. 2011, Maurer, Garrenton et al. 2012, Rosnizeck, 
Spoerner et al. 2012, Sun, Burke et al. 2012, Ostrem, Peters et al. 2013). However, since 
this discovery, only one study has found a selective compound, a key feature in 
personalized medicine, was that by Ostrem, which required a G12C mutation for proper 
binding to K-Ras (Chapter 1).  
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Consistent with others, we found that NMR and crystal structures have unique 
conformational differences (Andrec, Snyder et al. 2007) and the implications of such 
differences are immensely important for selectivity (Furnham, Blundell et al. 2006). 
However, the ability of computational methods to identify lead compounds on flexible 
targets has left much to be desired (Schneider 2010). To better understand how receptor 
dynamics impacts ligand binding, we developed a protocol that simultaneously assays 
multiple pockets and scores the binding process by consistency. By considering 
multiple sites and not just a single site, the preference for a given pocket can be 
quantified using a signal-to-noise ratio (SNR). To enhance the SNR, two filters were 
developed. One removes infrequently sampled poses and the other scales down low 
intensity protein-ligand contacts. The method in sum is called LIgand Binding 
Specificity Analysis (LIBSA). In LIBSA, the success of the docking experiments is 
contingent upon repetition and not solely based on affinity. This process inherently 
allows for multiple protein conformations to be used in the screening process.  
 
A validation study was carried out using a combination of re-docking and cross-docking 
experiments to demonstrate the ability of LIBSA to identify known binding sites. Using 
10 representative structures from 5 different protein families (kinase, protease, GPCR, 
G-proteins, nuclear receptors), the re-docking experiments succeeded in 9 out of 10 
instances and therefore suggest that this approach is applicable to a wide variety of 
systems. Importantly, the SNR is a convergent quantity and has low coefficient of 
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variation (<0.3) after 100 docking runs. This approach helps remove the bias that is 
associated with ranking by docking scores (Chapter 3).  
 
Given the recent discovery of several Ras binders, the LIBSA protocol was used to 
probe an ensemble of Ras conformers (>200) with a conservative set of ligands (~50) to 
identify hits that target known binding sites (Grant, Lukman et al. 2011). The receptor 
ensemble contains structures of wild type and mutant H- and K-Ras sampled from 
computational and experimental methods. By analyzing the aggregate ability of a set of 
probe compounds to bind the ensemble, isoform and mutant specific binding patterns 
could be determined with LIBSA.  
 
To discriminate between wild type H- and K-Ras, ligands that bind to p1 hold the most 
promise. For instance, H-Ras samples predominantly from a classic GTP-like 
conformation, while K-Ras samples from a state-1 intermediate conformation. This 
allows for compounds that target p1 in this alternate conformation to discriminate 
between the isoforms. Binding ligands at p2, showed little indication of being selective 
on either the isoform or mutant level. However, p3a showed the most promise for 
discriminating between wild type and the Q61H and Q61L isoforms because wild type 
K-Ras rarely binds ligands at this site. Importantly, LIBSA allowed for several 
compounds to be developed that target p1 and p2 (Chapter 4).  
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Andrographolide (AGP) is reported to have anti-inflammatory and anti-cancer 
properties (Hung, Hung et al. 2010). To explore if the anti-cancer activity of AGP and 
its benzylidene derivatives (Jada, Matthews et al. 2008), is possibly due to direct 
interaction with Ras, ensemble docking was carried out against K-RasQ61H. Using a 
probabilistic binding model similar to that of LIBSA, the probability of each docked 
pose was determined by weighting against both the ligand and receptor cluster sizes. 
This allowed for the most likely poses at multiple pockets to be determined. Using this 
approach, the ligand SRJ23 was found to bind two regions on Ras: switch 1 and β-
strands 1-3 along with parts of switch 2. Subsequent MD simulations of the docked 
complexes revealed that binding to the switch 1 (p1) region of Ras was stable and 
unstable at the alternate site (p2). After relaxing the complex of SRJ23 with K-Ras, 
switch 2 was found to undergo a conformational change where Y64 and Y71 adopted a 
conformation that resembled structures bound to small molecules shown to inhibit 
exchange factor binding (Maurer, Garrenton et al. 2012, Sun, Burke et al. 2012).  
 
Next, the ability of SRJ23 to inhibit the GTP loading of wild type K-Ras was assessed. 
As expected, EGF mediated guanine nucleotide exchange was inhibited in the presence 
of the AGP and the SRJ compounds using a pull-down assay, which recognizes only 
GTP bound Ras.  When repeated with oncogenic Ras, no discernible decrease in GTP 
loading over 6 hours was observed. It was concluded that this was due to the long half-
life of GTP on Ras due to its resistance to GAPs.  By simply extending the incubation 
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time, SRJ23 was indeed able to inhibit the GTP loading of oncogenic Ras (G12V-Kras).  
Collectively, this paints a very novel conclusion. Despite the long half-life of GTP 
binding, oncogenic Ras still requires guanine exchange factors to activate it, thus 
demonstrating that oncogenic Ras is not constitutively bound to GTP but is simply 
predominantly bound to GTP. Moreover, SRJ23 preferentially inhibited K-Ras over H-
Ras, which is consistent with p1 exhibiting an isoform specific binding profile. In 
summary, receptor dynamics play a fundamental role in ligand binding and therefore in 
drug discovery and needs to be explored in subsequent studies (Chapter 5).  
 
Future work should include the efficient identification of ligand probes that sample 
from drug-like space. Such a probe library should then be screened against a library of 
Ras conformations and evaluated with LIBSA. In particular, the use of new types of 
hardware such as graphics processor units (GPUs) and Intel Xeon Phi Coprocessors 
would aid in decreasing compute time during the post-docking analysis. This will allow 
for more efficient CADD projects to be carried out and in the long run would decrease 
the amount of time and money required to bring new drugs to market.  
 
 
 
 
127 
Appendix A 
 
Figure A1. Convergence of the SNRs with (red) and without (blue) the affinity filter. 
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Figure A2. Unfiltered ensemble contact spectrum for receptor clusters 1 to 5 for SRJ23. 
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Table A1 Summary of the MD trajectories for the various Ras systems.   
Receptor 
Variant 
Average 
Core Cα 
RMSD (Å) 
Clustering 
Cutoff 
(Å) 
%Conformers 
in top 10 
clusters 
Number 
Conformers 
(10 ps skip) 
Simulation 
Length (ns) 
WT K-Ras 0.53±0.01 1.3 92 40,000 400 
WT H-Ras 0.64±0.04 1.3 99 40,000 400 
K-RasG12V 0.54±0.01 1.8 99 20,000 200 
H-RasG12V 0.91±0.15 1.7 95 20,000 200 
K-RasQ61H 0.50±0.01 1.7 99 30,000 300 
H-RasQ61H 0.85±0.04 1.7 99 30,000 300 
K-RasQ61L 0.92±0.13 1.5 99 20,000 200 
H-RasQ61L 0.66±0.02 1.5 97 20,000 200 
  Totals 220,000 2,200 
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Table A2 The SNR for the various systems was calculated using 100-256 docked poses. 
The mean SNR value plus or minus the standard deviation was calculated with and 
without the affinity filter.  
Ligand SNR  
 Affinity Filter No Filter 
Gleevec 1.45±0.01 1.43±0.02 
0QW 1.84±0.04 1.27±0.02 
0QV 3.54±0.00 1.16±0.02 
BZI 3.48±0.00 1.07±0.03 
BI-167107 1.08±0.05 1.17±0.02 
Indinavir 0.93±0.01 0.98±0.04 
Nilotinib 1.14±0.04 1.11±0.01 
Tamoxifen 3.74±0.00 2.10±0.04 
Raloxifene 1.77±0.09 1.49±0.02 
Estradiol 3.64±0.00 3.64±0.00 
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Table A3. Isoform based comparison of ligand binding selectivity.  
 Wild Type Hit Frequencies (H-Ras, K-Ras) 
Ras Pocket Receptor Cluster GTP/GDP* GTP/State-1* GTP State-1 
p1 None, Medium Low, Medium High, None None, None 
p2 None, Low None, Low Low, None None, None 
p3a None, Medium Low, Low Low, None None, None 
p3b None, Low None, None Low, None None, None 
 G12V Hit Frequencies (H-Ras, K-Ras) 
 Receptor Cluster GTP/GDP* GTP/State-1* GTP State-1 
p1 High, Medium None, Medium Medium, None None, None 
p2 Low, Low Low, Low None, None None, None 
p3a Low, Medium None, Low Low, None None, None 
p3b Low, Low None, None None, None None, None 
 Q61L Hit Frequencies (H-Ras, K-Ras) 
 Receptor Cluster GTP/GDP* GTP/State-1* GTP State-1 
p1 None, Medium High, Medium Low, Medium Medium, Medium 
p2 None, None Low, Low None, None None, None 
p3a None, Low Low, Low Low, Low Low, Low 
p3b None, None None, None None, None None, None 
 Q61H Hit Frequencies (H-Ras, K-Ras) 
 Receptor Cluster GTP/GDP* GTP/State-1* GTP State-1 
p1 None, Low Low, High Medium, Medium None, None 
p2 None, None None, Low Low, Low  None, None 
p3a None, Low Low, Low Medium, Low None, None 
p3b None, Low None, Low None, None None, None 
The hit frequencies are defined as follows: None is zero hits (white); Low is <25 Hits 
(yellow); Medium is ≥25 and <100 hits (blue); High is ≥100 hits (green). Hit 
frequencies with the most difference (i.e. potential for selectivity) are highlighted in 
green, with less potential highlighted in blue and with no difference in black. 
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Appendix B 
MD simulation of K-Ras with docked SRJ23: Missing hydrogen atoms on the K-Ras-
SRJ23 complex were rebuilt using the CHARMM generalized force field (CGenFF) 
(Vanommeslaeghe, Hatcher et al. 2010) parameters for SRJ23 and the CHARMM all-
atom force field (MacKerell, Bashford et al. 1998) for the rest of the system. The 
complex was solvated in a 60Å x 60Å x 65Å box of TIP3 water and neutralizing 
counter ions were added with VMD and PSFGEN (Humphrey, Dalke et al. 1996).  The 
system was first relaxed by fixing all protein, GTP, and ligand heavy atoms applying 
2000 steps of conjugate gradient energy minimization, heated to a final temperature of 
310K over 50ps, and equilibrated for 500ps applying restraints with a progressively 
decreasing force constant of 4 kcal/mol/Å2 on backbone atoms. During equilibration we 
used an integration time step of 1fs, a non-bonded cutoff length of 10Å and a switching 
distance of 12Å. After equilibration, the integration time step was increased to 2fs with 
all bonds involving hydrogen atoms restrained with SHAKE, and the non-bonded cutoff 
length and switching distances were decreased to 8.5 and 10 Å respectively (Andersen 
1983). Long-range electrostatic interactions were treated using the particle mesh Ewald 
(PME) method (Darden, York et al. 1993). All simulations were performed with 
NAMD (Phillips, Braun et al. 2005) 
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Docking protocol and controls: The receptor structure was prepared by removing non-
polar hydrogen atoms and re-building polar hydrogen atoms with AutoDock tools, 
followed by assignment of charges based on the Gasteiger-Marsili method (Gasteiger 
and Marsili 1980). As mentioned in the main text, blind docking was carried out on the 
entire surface of the protein (i.e., without specifying a pocket). The receptor was kept 
rigid while rotatable bonds of the ligand were allowed to be flexible and the GTP (but 
not Mg2+) was retained to exclude non-specific hits at the catalytic site. The number of 
hybrid Lamarkian genetic algorithm runs was set to 256, the maximum number of 
generations to 10,000 and the Solis and Wets local search probability was increased 
from 0.06 to 0.10. This combination of parameters returns the best results without 
compromising performance (Grant, Lukman et al. 2011). The predictive ability of the 
protocol was also tested by blind docking Tamoxifen to ERα (PBB 3ERT), Nilotinib to 
p38 MAPK (3GP0), BZIM to K-Ras (4DSU), DCAI to K-Ras (4DST) and GTP to an 
MD-derived K-Ras structure. Except for DCAI the binding site and ligand pose of was 
correctly identified in each case (Fig. B1). 
 
Pocket identification: After ranking of ligand-receptor pairs as described in the 
Methods (main text), visual identification of binding sites was facilitated by contact 
histograms defined by a 4.0Å distance cutoff between any heavy atom on Ras and the 
top 5 cluster representatives of each ligand. Because the highest affinity ligand pose 
may not always be part of the most populated cluster, the best pose at each site was 
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selected manually on the condition that the pose shares the same binding site as the 
most populated ligand cluster. Thus, we used ligand cluster size for pocket 
identification and manual selection for the best pose at a particular site, with the 
premise that the best docking results occur when there is an overlap between ranking by 
cluster size and energy. Ligands were clustered using a cutoff of 2.0 Å.   
 
The role of halogen modification of AGP for binding to Ras: Since the halogen 
atoms on SRJ were shown to modulate cell cycle arrest and apoptosis (Jada, Matthews 
et al. 2008), we checked whether they also modulate binding to p1 or p2 by performing 
a series of modifications to two docked poses of SRJ23 and re-scoring the modified 
ligands. Though the AutoDock score for p1 slightly improved upon removal of chlorine 
and replacement of fluorine by bromine (-9.6 kcal/mol to -10.1 kcal/mol), the halogen 
atoms do not appear to have much effect. We note however that affinity and function 
are not always directly linked.  
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Figure B1 Docking controls for 4 of 5 attempted systems.  For the Nilotinib-p38 
MAPK, BZIM-K-Ras, Tamoxifen-ERα, and GTP-K-Ras systems we successfully 
identified the correct binding site as well as approximately recreated the correct ligand 
pose. We were unable to replicate DCAI bound to K-Ras with a high degree of 
certainty.   
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Figure B2 Binding hotspot analysis of the crystal structure of K-RasQ61H (PDB ID 
code 3GFT) and two MD-derived conformers using FTMap. The probe molecules 
readily identified the GTP binding site in all three structures, as well as one or more of 
allosteric sites p1, p2, and p3, whose accessibility changes with dynamics. To facilitate 
visualization of the allosteric pockets, all Ras residues within 4.0 Å of GTP that are not 
part of p1 or p2 were assigned a binding probability of zero. The rest of the molecular 
surface was colored such that the residues that most readily interact with the probe 
molecules are in red and those with zero probability are in black; the greenish yellow 
surface denotes intermediate interaction. Shown here are the front and back views of 
three representative structures (see main text and Figure B7): the X-ray structure PDB 
ID code 3GFT with closed p1 (A and B); the centroid of cluster 2 (C and D); and the 
centroid of cluster 48 (E and F). The probes targeted p2 and p3 in the crystal structure, 
p1 and p3 in cluster 2, and only p1 in cluster 48. 
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Figure B3 SRJ23 stabilizes an open switch 1 conformation during simulations. (A) 
Time evolution of the distance between D33 and D38 Cα atoms, which fluctuates 
around 11 Å in the absence (cyan) and 14 Å in the presence of SRJ23 (orange). (Inset) 
Backbone superposition of residues 30–40 of K-RasQ61H showing that D33 is 
relatively stable whereas D38 and Y40 differ in the presence and absence of the ligand 
when the receptor is in states 1 and 2. The state 1 conformation of K-RasQ61H (orange) 
is more dynamic than state 2 (cyan), which is the classic effector binding conformation. 
As shown in Fig. S7, the movement of Y40 allows for pocket 1 to open up, which aids 
ligand binding. (B) Opening of p1 is facilitated by the displacement of Y40 away from 
its orientation often seen in crystallographic structures of GTP-Ras. The switch 1 region 
shown is an MS/MS surface and is colored by the electrostatic potential. For 
comparison, Y40 is shown in two conformations, in state 1 (labeled in black) and state 2 
(cyan van der Waals spheres), highlighting the potential for a ligand to occupy the space 
left open by the reorientation of Y40 and the expansion of the pocket (see also Fig. 3C). 
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Figure B4 Overview of the dynamics required for the opening of p1 and p2.  (A) Pocket 
1 in the closed form.  (B) Pocket 2 in the closed conformation where the binding groove 
is shortened. (C) Expansion of pocket 1 due to the re-orientation of Y40 (see Figure B2 
& B3) that provides access to a binding pocket.  (D) Pocket 2 binding groove in the 
open conformation. 
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Figure B5 Binding frequency histogram for AGP, SRJ09, SRJ10, and SRJ23 in 
aggregate to each of the 75 K-Ras conformers. Contacts were defined based on a simple 
heavy atom distance cutoff of 4 Å between the ligand of interest and the receptor.  The 
histograms show that AGP can interact with three distinct regions on Ras: pockets p1 
(peaks involving switch 1 residues 24-40), p2 (peaks involving switch 2 residues 57-
75), and p3 (peaks in the C-terminal half of the protein residues 87-166). The SRJ 
derivatives rarely target p3 and prefer p1 or p2.   
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Figure B6 (A) RMSD calculations of SRJ23 bound at p1 (blue) and p2 (red). SRJ23 in 
complex with Q61H-K-Ras bound at pockets p1 (C&D) and p2 (B&E) after relaxation 
with MD. Although the p2-bound SRJ23 repeatedly dissociated during the simulations 
it is nonetheless remarkable that it occupies a similar pocket as those described by 
Maurer et al (Maurer, Garrenton et al. 2012) and Sun et al (Sun, Burke et al. 2012). 
Note the halogenated phenyl ring occupying the hydrophobic pocket with V7 being 
right underneath (see main text Figure 5.3D).   
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Figure B7 (A) Depiction of an SRJ23 fragment bound to p1 on K-RasQ61H. Switches 1 
and 2 are shown as blue and green surfaces and p1 is in orange; the transparent gray 
surface represents the rest of the protein. Pocket 1 is outlined in a red box and the 
docked molecule, fragment 11, which docked onto this site in the same pose in all 256 
cases, is shown at the top right. (B) Distribution of docked ligands sorted in an 
ascending order by their Vina score. Each curve represents the score of 940 ligands 
screened against the indicated Ras conformer, and the black square on each curve 
denotes the score for SRJ23 when docked on the same conformer. Left shift signifies 
higher affinity. For each conformer, the backbone of switch 1 and the orientation of 
D33, D38, and Y40 are shown (Inset) to illustrate the key conformational changes 
accompanying p1 opening: p1 is open in clusters 2 and 48, closed in cluster 1, and 
semiopen in clusters 4, 7, and 37. (C) Chemical structure of representative scaffolds for 
the top-scoring compounds, with sites of frequent substitution indicated by R. 
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Figure B8 Principal Component (PC) analysis of K-Ras in the absence (A) and presence 
(B) of SRJ23.  (A) Conformers from three independent 100ns-long trajectories of Q61H 
K-Ras (blue) were projected onto a plane defined by the first two PCs of available 
crystal structures. (B) A similar projection of conformers from a 100ns-long trajectory 
of Q61H K-Ras/SRJ23 (bound at p1). The remaining four trajectories of K-Ras/SRJ23 
yielded similar conformer distributions. 
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Figure B9 Mean fold-increase in in Ras-GTP (A) and ppERK (B) ± SEM from 3 
independent experiments where wild type BHK cells were treated with AGP for 6h in 
the absence of serum, followed by 25 ng/mL EGF stimulation for 2min. Ras-GTP levels 
were measured using an RBD pull-down assay and ppERK levels measured by 
quantitative immunoblotting. Differences between DMSO- and drug-treated cells were 
assessed using one-way ANOVA tests. Significant differences are indicated (*, p>0.05). 
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Figure B10 Overlay of 10 of each of the H- and K-Ras structures sampled form 400-ns 
MD simulations. The most dynamics switch 1 and 2 regions are shown in purple (H-
Ras) and orange (K-Ras). Note the substantially more open switch 1 conformations in 
K-Ras.  
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Figure B11 Mean ppERK ±SEM from three independent experiments where BHK cells 
ectopically expressing constitutively active CRaf (Y340D, Y341D) were treated with 25 
µM sorafenib (SF) or 5 µM SRJ09 for 6 h. A representative blot from three independent 
experiments is shown. 
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Table B1 1H NMR spectral data for compounds AGP, SRJ09 and SRJ23. 
1H 
1H NMR 
AGP SRJ09 SRJ23 
3 3.86 (1H, d, J = 10.5) 3.70 (1H, dd, J = 12.7, 4.7) 3.57 (1H, dd, J = 12.5, 5.0) 
9 2.48* 2.56* 2.34 (1H, m) 
11 2.48* 2.56* 2.45 (2H, m) 
12 6.64 (1H, t, J = 6.5) 7.00 (1H, t, J = 7.0) 6.82 (1H, t, J = 7.0) 
14 5.07 (1H, d, J = 6.0) 5.07 (1H, d, J = 6.0) 4.90 (1H, d, J = 5.5) 
15 4.42 (1H, dd, J = 10.5, 6.0) 4.49 (1H, dd, J = 10.5, 6.0) 4.34 (1H, dd, J = 10.5, 5.5) 
 4.06 (1H, dd, J = 10.5, 1.5) 4.28* 4.14 (1H, m) 
17 4.84 (1H, s) 4.95 (1H, s) 4.82 (1H, s) 
 4.65 (1H, s) 4.66 (1H, m) 4.56 (1H, s) 
18 1.10 (3H, s) 1.51 (3H, s) 1.35 (3H, s) 
19 4.16 (1H, m) 4.28* 4.14 (1H, m) 
 3.36 (1H, d, J = 11.5) 3.64 (1H, d, J = 11.0) 3.48 (1H, d, J = 11.5) 
20 0.68 (3H, s) 0.92 (3H, s) 0.78 (3H, s) 
21  6.08 (1H, s) 5.62 (1H, s) 
23   7.55 (1H, d, J = 7.0) 
24  7.76 (1H, d, J = 8.0)  
25  7.37 (1H, t, J = 8.0)  
26  7.22 (1H, dd, J = 7.5, 1.5) 7.04 (1H, dd, J = 8.0, 1.5) 
27  7.54 (1H, d, J = 8.0) 7.26 (1H, m) 
δ, ppm; d, doublet; dd, doublet of doublets; J, multiplicity in Hz; m, multiplets; s, 
singlet; t, triplet. *Obscured by overlapping with other signals. 
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Table B2 13C-NMR spectral data for compounds AGP, SRJ09, and SRJ23. 
 
13
C-NMR 
Carbon AGP SRJ09 SRJ23 
1 37.1 36.1 36.2 
2 28.5 26.1 26.2 
3 79.1 81.3 81.0 
4 42.9 38.9 39.1 
5 55.0 55.9 55.0 
6 24.6 22.9 23.0 
7 38.1 37.0 37.1 
8 148.2 148.6 148.9 
9 56.1 54.9 55.9 
10 39.2 37.7 37.7 
11 24.5 24.7 24.9 
12 147.0 146.6 146.6 
13 129.5 132.7 129 
14 65.2 69.9 69.7 
15 75.0 74.9 74.5 
16 170.6 171.1 170.1 
17 108.9 109.4 109.5 
18 23.6 21.7 21.9 
19 63.3 65.7 66.4 
20 15.4 15.4 15.5 
21 
 
94.5 93.9 
22 
 
137.5 136.2 
23 
 
122.4 128.3 
24 
 
130.5 116.4 
25 
 
128.3 156.7 
26 
 
127.8 116.2 
27 
 
128.2 126.4 
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